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SUMMARY 
The Na+-Ca2+ exchanger 1 (NCX1) is reduced in stroke by the RE1-silencing 
transcription factor (REST), whereas it is increased in Ischemic Brain 
Preconditioning (PC) by Hypoxia-Inducible Factor 1 (HIF-1). Since ncx1 brain 
promoter (ncx1-Br) has five putative consensus sequences for the Specificity 
protein (Sp) family of transcription factors (Sp1, Sp2, Sp3, Sp4), named Sp1 
A-E, we investigated the role of this family in regulating ncx1 transcription in 
cortical neurons. Here we found that Sp1 is a transcriptional activator, 
whereas Sp3 is a transcriptional repressor of ncx1, and that both bind ncx1 
brain promoter (ncx1-Br) in a sequence-specific manner, modulating ncx1 
transcription through the Sp1 sites C-E. Furthermore, in brain ischemia 
(tMCAO) the transcriptional repressors Sp3 and REST colocalize with 
histone-deacetylases (HDACs) HDAC1-2 at the ncx1 promoter, with a 
consequent hypoacetylation. By contrast, in PC+tMCAO the transcriptional 
activators Sp1 and HIF-1 colocalize with Histone-Acetyltransferase p300 
(p300) on ncx1 promoter sequence with a consequent hyperacetylation. 
Moreover, when brain ischemia-induced REST and Sp3 up-regulation was 
prevented by intracerebroventricular (icv) injection of siRNAs for REST and 
Sp3, NCX1 downregulation was reverted. Interestingly, also siRNAs for 
HDAC1-2 was able to completely revert NCX1 reduction. On the contrary, 
siRNA for Sp1 and HIF-1, during PC+tMCAO, blocked NCX1 increase, that 
was almost completely reverted by double siRNA for HIF-1 and Sp1 or by 
siRNA for p300. In addition, in neurons transfected for siNCX1, and 
subjected to Oxygen Glucose Deprivation (OGD) (3 hours) plus 
Reoxygenation (RX) (24 hours), the protective effect of class I HDAC inhibitor 
MS-275 was counteracted, whereas neurons overexpressing NCX1 and 
subjected to ischemic preconditioning (PC+OGD\Rx), the detrimental effect 
of p300 inhibitor C646 was prevented. Collectively, these results demonstrate 
that NCX1 expression is regulated by Sp3\REST\HDAC1-2 complex in 
tMCAO and by the Sp1\HIF-1\p300 complex in PC+tMCAO, and that 
epigenetic therapy modulating the acetylation of ncx1 gene promoter may be 
a new strategy to reduce the neurodetrimental effect of stroke. 
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I. INTRODUCTION 
I.A. CEREBRAL ISCHEMIA 
Ischemic stroke, is the third leading cause of death and a major cause of 
long-lasting disability in industrially developed countries, only surpassed by 
heart disease and cancer. It is a pathological condition resulting from 
occlusion or hemorrhage of blood vessels supplying oxygen and essential 
nutrients to the brain. In all cases, stroke ultimately induces death and\or 
dysfunction of brain cells, as well as neurological impairments that reflect the 
location and size of the ischemic brain area. Even though a large number of 
compounds have been prove to reduce ischemic injury in experimental 
animal models, clinical trials have reported disappointing results because of 
toxic side effects. At present the only FDA (US Food andDrug Administration) 
approved treatment is to provide tissue plasminogen activator (tPA) to re-
open occluded blood vessels, however, due to a narrow time-window of 4,5 
hours after the stroke onset (Hacke et al., 2008), this treatment is only 
appropriate for every small number of patients. Thus, research on the 
discovery of novel mechanisms and the development of new drugs for 
treating cerebral ischemia are imperative. 
 
I.A.1. Pathophysiology of Cerebral Ischemia 
Cerebral ischemic event triggers a set of complex pathological mechanisms 
eventually leading to death and\or dysfunction of brain cells. Excitotoxicity 
and ionic imbalance, oxidative\nitrosative stress, inflammation and apoptosis 
are some of the ischemia-induced pathophysiological processes, each of 
which has a distinct time frame, some occurring over minutes, others over 
hours and days, causing injury to neurons, glia and endothelial cells. Within 
the core of the ischemic area, where blood flow is most severely restricted, 
excitotoxic and necrotic cell death occurs within minutes. In the periphery of 
the ischemic area, where collateral blood flow can buffer the full effects of the 
stroke, the degree of ischemia and the timing of reperfusion determine the 
outcome for individual cells. In this ischemic penumbra cell death occurs less 
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rapidly via mechanisms such as apoptosis and inflammation (Dirnagl et al., 
1999). 
 
I.A.1.1. Excitotoxicity and Ionic imbalance 
After ischemia, Na+\K+-ATPase and Ca2+-ATPase, which are important ion 
pumps found on the plasma membrane of neurons, can no longer function 
due to energy depletion. Their impaired functions cause neuronal plasma 
membrane depolarization, release of potassium into the extracellular space 
and entry of sodium and calcium into the cells (Caplan, 2000). Consequently, 
calcium dependent proteases, lipases and DNases become active, 
eventually leading to catabolism and death of many cells in the ischemic 
core. Furthermore, membrane depolarization results in neurotransmitter 
release, most prominently the release of the excitatory neurotransmitter 
glutamate, which plays a central role in the pathology of cerebral ischemia 
(Simon et al., 1984). Increase in synaptic glutamate concentration 
overactivates its receptors, N-methyl-D-aspartate (NMDA) and α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and metabotropic 
glutamate (mGlu) receptors, which in return cause further membrane 
depolarization and greater calcium influx, exacerbating excitotoxicity (Bruno 
et al., 2001; Peng et al., 2006). 
 
 
Figure 1. Damaging cascades of events after cerebral ischemia (Dirnagl et al., 1999). 
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I.A.1.2. Oxidative and nitrosative stress 
Unlike other organs, the brain is especially vulnerable to reactive oxygen 
species due to neurons having relatively low levels of endogenous 
antioxidants (Coyle and Puttfarcken, 1993). High levels of intracellular 
calcium, sodium and ADP induce mitochondria to produce deleterious levels 
of reactive oxygen species, and consequently overly abundant oxygen 
radicals cause the destruction of cellular macromolecules and participate in 
signaling mechanisms that result in apoptotic cell death (Sugawara and 
Chan, 2003). Moreover, there is a surge in production of superoxide, NO and 
peroxynitrate, following reperfusion. Thrombolytic therapy has a 4,5 hour time 
window of efficacy. The reason for this limited time window is that the surge 
in production of free radicals associated with delayed reperfusion brings a 
second wave of oxidative and nitrosative stress that increases the risk of 
brain hemorrhage and edema. 
 
I.A.1.3. Apoptosis 
Ischemic injury preferentially induces cell death via an apoptotic-like 
mechanism rather than necrosis. Because the ischemic penumbra sustains 
milder injury and preserves ATP, apoptosis predominates in this region 
(González, 2006). Triggers of apoptosis include ionic imbalance, oxygen free 
radicals, death receptor ligation, DNA damage and protease activation. 
Cytochrome c release from the outer mitochondrial membrane, an event 
which is promoted or prevented by Bcl-2 family of proteins, initiates the 
intrinsic apoptotic cascade. In addition, extrinsic apoptosis pathway, which 
could be activated by inflammatory signals such as TNF family of ligands, is 
also operative after ischemia (del Zoppo et al., 2000). Eventually, 
downstream effector caspases are activated targeting the substrates that 
dismantle the cell by cleaving homeostatic, cytoskeletal, repair, metabolic 
and cell signaling proteins (Namura et al., 1998)  
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I.A.1.4. Inflammation 
Inflammation contributes to cerebral ischemic injury. Effects of individual 
components of the inflammatory cascade, however, can be beneficial 
depending on the stage of tissue injury, the magnitude of the response and 
whether the inflammatory component also activates neuroprotective 
pathways (Bruce et al., 1996; Nawashiro et al., 2000). After stroke immune 
cells can gain access to brain parenchymal tissue. Infiltration of bone 
marrow-derived cells into the ischemic brain persists for weeks following 
stroke, and while the initial infiltration leads to worsening of tissue damage 
and exacerbation of neurological deficits, subsequent aspects of the 
infiltration such as the phagocytosis of debris and the release of cytokines 
that promote glial scar formation could be crucial for effective wound healing. 
On the other hand, numerous cytokines and chemokines are produced by 
activated endothelial cells, microglia, neurons, platelets, leukocytes, and 
fibroblasts and contribute to ischemic brain injury (Gong et al., 1998). In 
particular, IL-1, TNF-α and toll-like receptors (TLRs) are important 
inflammatory factors with detrimental effects for stroke outcome (Zaremba 
and Losy, 2001; Cao et al., 2007; Lehnardt et al., 2007). In contrast, TGF-β 
was reported to play a neuroprotective role in the pathogenesis of stroke 
(Wiessner et al., 1993). 
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Figure 2. Depiction of the major pathophysiological events evoked by cerebral ischemic injury. 
Glutamate excitotoxicity, peri-infarct depolarisations, oxidative\nitrosative stress, apoptosis and 
inflammation contribute to injury following brain ischemia (Dirnagl et al., 1999).  
 
I.A.2. Ischemic preconditioning in brain 
Ischemic preconditioning or ischemic tolerance is described as a brief 
episode of sub-lethal ischemia which renders the brain resistant to 
subsequent, longer and severe ischemic insults. The terms 'tolerance' and 
'preconditioning' were introduced for the first time by Janoff in 1964 
(JANOFF, 1964), and ever since, the phenomenon of ischemic 
preconditioning has been observed in numerous organs such as brain 
(Kitagawa et al., 1991) and heart (Meldrum et al., 1997), as well as in a wide 
range of species like the gerbil (Kirino et al., 1991), the rat (Simon et al., 
1993) and the mouse (Wu et al., 2001). Amongst various brain regions, 
hippocampus, cerebral cortex, basal ganglia and thalamus were often 
reported to acquire ischemic tolerance (Kitagawa et al., 1991). Measurement 
of cerebral blood flow showed that such tolerance was not accompanied by 
an improvement of regional tissue perfusion during or after the ischemic 
episode that induced tolerance (Matsushima and Hakim, 1995; Barone et al., 
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1998). Therefore, the state of ischemic tolerance seems to be based on the 
alteration of neurons themselves at the cellular level. 
 
I.A.2.1. Mechanisms of Ischemic Preconditioning 
Mechanisms of ischemic preconditioning could be grouped into three 
components according to the temporal profile of their development. The first 
component is the stress sensor\signalling component that can detect various 
stressful conditions and convert the information into intracellular signals. 
Hypoxia Inducible Factor (HIF), oxygen sensitive ion channels, potassium 
channels, calcium and sodium channel families control cellular responses for 
hypoxia in neurons as well as in many other cell types and belong to the 
sensor\signaling component of tolerance development (Kemp and Peers, 
2007). Once the danger is detected by the cell, an appropriate cellular 
response is coordinated by the transducer component, which includes 
various kinases such as p38 mitogen activated protein kinase (MAPK) 
(Nishimura et al., 2003) and extracellular regulated kinases (ERK) (Jones 
and Bergeron, 2004), as well as transcription factors like signal transducer 
and activator of transcription (STATs), cyclic AMP response-element binding-
protein (CREB) (Meller et al., 2005) and nuclear factor kappa B (NF-κB) 
(Digicaylioglu and Lipton, 2001). Lastly, the effector component represents 
the executive mediators of protection: Reactive oxygen species (ROS) 
scavenger superoxide dismutase (SOD) (Danielisová et al., 2005), anti-
apoptotic protein Bcl-2 (Liu et al., 2002), vascular endothelial growth factor 
(VEGF) (Bernaudin et al., 2002), nitricoxide (NO) and hexokinase-2 are some 
of the most reported mediators of neuroprotection conferred by ischemic 
preconditioning (Kirino, 2002). Ischemic preconditioning-induced 
neuroprotection may be the result of a combination of different cellular and 
molecular pathways, with a net outcome of counteracting pathophysiological 
cascades triggered by lethal ischemic insult. Ischemic tolerance thus reflects 
a fundamental change in the cellular response to injury that shifts the 
outcome from cell death to cell survival (Dirnagl et al., 2003). In fact, Stenzel-
Poore, with a substantial series of genome-wide gene expression analysis 
study, suggested that preconditioning maylead to a fundamental 
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reprogramming of the transcriptional response to ischemic injury, ultimately 
conferring neuroprotection (Stenzel-Poore et al., 2003). Although 
transcription factors, such as HIF-1, CREB and NF-κB are already known to 
be driving neuroprotective gene expression upon an ischemic preconditioning 
stimulus, we are today more aware that apart from the transcription factors 
and DNA sequence, regulation of such transcriptional activity requires the 
cooperation of a third party, namely epigenetic alterations of the DNA and 
histones. Indeed, these modifications crucially regulate the accessibility of 
specific regulatory DNA elements for transcription machinery. Recent years 
have witnessed the emergence of growing evidence supporting an integral 
role for epigenetic mechanisms in neuronal gene expression, yet involvement 
of these mechanisms in brain ischemic preconditioning and neuroprotection 
is mostly unknown. 
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I.B. EPIGENETICS 
Epigenetics has historically meant “on top of, or in addition to, genetics”. 
Epigenetics was initially considered to have a role mainly in development and 
cell differentiation, thus allowing cells with identical genomes to acquire 
distinct phenotypes based on genetic programming. Today, epigenetics is 
accepted as the study of modifications that result in heritable changes in 
gene expression independent of alterations in DNA sequence. These major 
epigenetic modifications include DNA methylation, histone modifications and, 
more recently, RNA interference, i.e. through non-coding microRNA (miRNA) 
(Konsoula and Barile, 2012). 
 
I.B.1. Nucleosome 
The nucleosome core particle is the fundamental unit of chromatin structure 
in all eukaryotes. It is an octamer, containing two copies of each of the four 
histone proteins, H2A, H2B, H3, H4, and around which 146 bp of DNA is 
wrapped in 1¾ superhelical turns (Luger et al., 1997). All core histone 
proteins have a similar structure with an N-terminal domain, a globular 
domain and a C-terminal domain. It has been known for many years that the 
histone N-terminal tails are exposed on the surface of the nucleosome and 
that selected amino acid residues could be subjected to a variety of enzyme-
catalyzed, post-translational modifications. These include acetylation of 
lysines, phosphorylation of serines, and methylation of lysines and arginines, 
and addition of small peptide ubiquitin. The current epigenetics defines the 
nucleosome and its modified tail domains, not solely as a structural packer of 
DNA, but a carrier of epigenetic information that determines both how genes 
are expressed and how their expression patterns are maintained from one 
cell generation to the next. 
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I.B.2. Epigenetic Modifications 
Covalent histone modifications, DNA methylation and RNA-associated post-
transcriptional gene silencing have been so far the most investigated 
modifications that carry epigenetic information. The histone tail modifications 
are likely to act in concert with the rather more widely known mediator of 
chromatin structure and gene expression, namely methylation of cytosine 
residues in CpG dimers through the action of DNA methyltransferases. Long-
term silencing, as found in imprinted genes or the female inactive X 
chromosome, is generally associated with relatively high levels of CpG 
methylation. Current knowledge on the exact mechanism(s) by which CpG 
methylation leads to gene silencing is still fragmentary, yet there is evidence 
that histone modifications are also involved. Notably, experiments in the 
filamentous fungus Neurospora crassa have shown that DNA methylation is 
dependent upon methylation of histone H3 lysine 9 (Tamaru and Selker, 
2001). Recent studies have shed light on the complexity of epigenetic 
information that could possibly be carried in the histone tails. Currently, there 
are 50 different acetylated isoforms of the four core histones (H2B, H3, and 
H4 have 16 each and H2A has two). These isoforms can be modified further 
by methylation of selected lysines and arginines (H3 and H4) and 
phosphorylation of serine (H3, H4, H2B). Moreover, methylation can be 
attachment of one, two, or three methyl groups, and there are other 
modifications, such as ubiquitination and ADP-ribosylation (Hansen et al., 
1998). The total number of possible histone isoforms, carrying different 
combinations of tail modifications can reach a total sum of many thousands. 
This vast information carrying potential of histone tail modifications have 
given rise to the concept of a histone code (Strahl and Allis, 2000) or an 
epigenetic code (Turner, 2000), which is expected to be much more 
sophisticated than the genetic code carried in DNA sequence. 
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I.B.3. Acetylation and Deacetylation 
Acetylation and deacetylation of histone proteins associated with chromatin 
plays a pivotal role in the epigenetic regulation of transcription and other 
functions in cells, including neurons (Mai et al., 2005; Abel and Zukin, 2008). 
Histone acetyltransferases (HATs) and histone deacetylases (HDACs) 
catalyze the acetylation and deacetylation, respectively, of histone proteins at 
Lys (K) residues. The interplay between HATs and HDACs alters the net 
balance of histone acetylation levels, thereby remodeling chromatin structure 
(Fig. 3). In general, an increase in protein acetylation at histone tails results 
in a more open and relaxed chromatin conformation, thus facilitating 
transcription factor interaction with specific gene promoters and activating 
gene expression. HDACs often function as a component of the transcriptional 
repressor complex to silence gene expression and induce chromatin 
compaction through histone protein deacetylation. Accordingly, HDAC 
inhibition shifts the balance towards enhanced histone acetylation, chromatin 
relaxation and gene expression. Imbalance between the activities of HATs 
and HDACs could lead to disease states. For example, mutation and loss of 
activity of the HAT, cyclic AMP response element binding protein (CREB)-
binding protein (CBP), is causative for Rubinstein–Taybi syndrome, a 
developmental disorder characterized by mental retardation (Bartsch et al., 
2005). In addition to histones, HATs and HDACs also use a number of non-
histone proteins as their substrates, notably tubulin and transcription factors 
such as the tumor suppressor p53, Sp1, Smad7, CREB, the pleiotropic 
transcription factor NF-kB, and signal transducers and activators of 
transcription-1 (STAT-1) (Chuang et al., 2009a). 
 
I.B.4. Histone Acetyltransferase (HAT) Families 
Histone acetyltransferases (HATs) are a group of enzymes which transfer the 
acetyl moiety from acetyl coenzyme A (acetyl Co A) onto one or more lysine 
residues contained within the N-terminal tails of histone proteins. Sequence 
analysis of HAT proteins reveal that they fall into distinct families that show 
high sequence similarity (Kuo and Allis, 1998). Each HAT family appears to 
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have a distinct substrate preference, and different families tend to appear in 
different functional contexts Gcn5\PCAF, MYST, TAFII250 and CREB-
binding protein (CBP)\p300 are some of the most studied HAT families. 
Among those, CBP\p300 family, including CBP and its close homologue 
p300, is fundamentally important in various signal modulated transcriptional 
events (Eckner et al., 1994). The ability of CBP\p300 to enhance transcription 
is believed to be accomplished in two modes. First, by acting as a bridging 
factor thus recruiting the RNA polymerase II holoenzyme via interaction with 
general transcription factors (Manteuffel-Cymborowska, 1999) and second, 
by acetylation of histones via their HAT activity (Ogryzko et al., 1996). 
Nucleosomal histones H3 and H4 are the preferred substrates. Both CBP 
and p300 proteins were shown to interact with a diverse set of sequence-
specific transcription factors such as E2F, p53, MyoD, c-Myb and HIV-tat 
(Snowden and Perkins, 1998). Homozygous knockout mice of either CBP or 
p300 display, among several other malformations, defects in neural tube 
closing and are embryonic lethal (Yao et al., 1998). 
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Figure 3. Effects of HDAC inhibitors on chromatin remodeling. Levels of histone acetylation at Lys 
residues on histone-tails are determined by interplays of acetylation and deacetylation catalyzed by 
histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. Inhibition of 
HDACs by HDAC inhibitors results in a net increase in histone acetylation levels and a more open, 
relaxed chromatin conformation that favors transcriptional activation. By contrast, chromatin with a 
compact conformation is transcriptionally inactive (Chuang et al. 2009). 
 
I.B.5. Histone Deacetylases (HDACs): Structure–Function Analysis 
The superfamily of HDACs consists of five main subtypes: classes I, IIa and 
IIb, IV, and the structurally distinct class III (Gregoretti et al., 2004; Butler and 
Bates, 2006). The name HDAC is a misnomer having a historic origin, as 
histones are not enzymatic substrates for some deacetylases in a given 
family, and are not exclusive substrates for other family members. Class I 
and class II HDACs include the Zn2+-dependent deacetylases, which share 
significant structural homology, especially within the highly conserved 
catalytic domains (Thiagalingam et al., 2003). 
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Class I HDACs contain the ubiquitously expressed HDAC1, HDAC2 and 
HDAC3, and the muscle-specific HDAC8. HDAC1 and HDAC2 are 
predominantly localized in the nucleus, whereas HDAC3 shuttles between 
the nucleus and cytoplasm. All three of these deacetylases contain a nuclear 
localization signal within their protein sequences, and HDAC3 additionally 
has a nuclear export signal (Yang et al., 2002). The best-characterized 
enzymes HDAC1 and HDAC2 are components of three stable transcriptional 
complexes termed Sin3A, NuRD and CoREST. These complexes are 
recruited to gene promoters by DNA binding proteins, which suggests gene 
specific rather then global transcriptional regulation (Laherty et al., 1997; 
Wen et al., 2000). 
Class IIa HDACs consist of four members — HDAC4, HDAC5, HDAC7 and 
HDAC9 — with distinct tissue specific patterns of expression, predominantly 
in muscle and heart (Majdzadeh et al., 2008). These proteins contain 
extended amino-terminal domains of ~600 aminoacids, which mediate 
interactions with HDAC3, myocyte enhancer factor 2 (MeF2), repressor 
complex NCoR2\SMRT and 14-3-3 proteins (Butler and Bates, 2006), 
followed by the Zn2+-containing catalytic domain. Interestingly, some data 
indicate that HDAC4, HDAC5 and HDAC7 are unable to deacetylate histones 
themselves, but probably participate in gene-specific transcriptional 
regulation via an interaction with class I HDAC3 (Fischle et al., 2001). 
However, new results have demonstrated intrinsic deacetylase activity of 
HDAC4 and other class IIa deacetylases, and have showed that these 
enzymes are particularly active on class IIa-specific substrates in vitro (Jones 
et al., 2008). HDAC4, HDAC5, HDAC7 and MITR shuttle between the 
nucleus and cytoplasm, whereas full-length HDAC9 is localized in the 
nucleus (Bertos et al., 2001; Petrie et al., 2003). Retention in the cytoplasm is 
controlled by 14-3-3 anchor proteins, which bind exclusively to the 
phosphorylated from of HDACs and prevent entry into the nucleus, whereas 
nuclear re-entry occurs upon protein dephosphorylation (Zhang et al., 2001; 
Grozinger and Schreiber, 2000). 
Class IIb HDACs include HDAC6 and HDAC10. The structure of HDAC6 is 
unusual in that it contains two independently functioning catalytic domains 
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and a carboxy-terminal Zn2+-finger ubiquitin binding domain. HDAC6 
functions in the cytoplasm where it deacetylates α-tubulin and alters 
microtubule stability (Hubbert et al., 2002; Matsuyama et al., 2002). Its close 
structural homologue HDAC10 lacks the second functional catalytic domain 
(Tong et al., 2002). HDAC10 has been found in a complex with HDAC3, 
although the exact functions of this deacetylase are not known. 
The class IV enzyme HDAC11 is structurally different from the class I and 
class II deacetylases. HDAC11 is predominantly localized in the nucleus. The 
function of this deacetylase is poorly understood, although region-specific 
and developmental expression patterns have been observed in the mouse 
brain, (Liu et al., 2008). 
By contrast, the class III deacetylases, or sirtuins, are structurally and 
functionally different from other HDACs. Named after the Silent information 
regulator 2 (Sir2) gene — the first sirtuin identified in budding yeast — in 
humans, the class III HDACs include seven members. Sirtuins are markedly 
different in their absolute dependence on NAD+ to carry out catalytic 
reactions, which include both deacetylase and mono-ADP-transferase 
activities (Sauve et al., 2006). The predominant deacetylase activity has 
been shown for the class III HDACs SIRT1, SIRT2, SIRT3 and SIRT5 (Gan 
and Mucke, 2008). The deacetylation reaction mediated by sirtuins is coupled 
to the cleavage of NAD+, yielding nicotinamide and 2′-O-acetyl ADP-ribose, 
along with the deacetylated lysine residue within the protein substrate (Denu, 
2005), (Denu J. M., 2005). Structurally, human SIRT1 is the closest analogue 
of yeast Sir2, which regulates cellular metabolism and ageing. SIRT2 has 
both nuclear and cytosolic localization, and interacts with numerous protein 
partners to execute multiple functions in cells. SIRT1 deacetylates a single 
lysine residue on several histones: K16 on histone 4 (H4), K14 on histone 3 
(H3) and K26 on histone 1 (H1). Non-histone substrates of SIRT1 include the 
transcription factors p53, TAFI68, p300 and peroxisome proliferator activated 
receptor-γ, coactivator 1α (PGC1α) (Michan and Sinclair, 2007). SIRT2 is a 
cytosolic protein that deacetylates α-tubulin and microtubules, a function that 
is redundant with that of HDAC6. Subsequently, it has been shown that 
SIRT2 also deacetylates K16 on H4 (Vaquero et al., 2006), and localizes to 
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neuronal nuclei. SIRT3, instead, is a mitochondrial protein. Acetyl-CoA 
synthetase (ACS2) has been identified as a SIRT3 substrate; however other 
data suggest a broad role for SIRT3 in regulating global mitochondrial lysine 
acetylation (Hallows et al., 2006; Schwer et al., 2006). Finally, SIRT6 has 
recently been shown to be involved in the regulation of telomomeric DNA 
during S phase where the putative enzymatic target is K9 on H3 (Kazantsev 
and Thompson, 2008). 
 
I.B.6. HDACs Inhibitors 
Intensive therapeutic development efforts have focused on targeting HDACs 
with small molecules. Initially, this interest was precipitated by the discovery 
of the anticancer potential of HDAC inhibitors. Subsequently, potential 
therapeutic applications were broadened to include other human illnesses, 
including CNS diseases, based initially on promising in vivo applications to 
polyglutamine-repeat diseases. Although cancer remains a primary target for 
HDAC-based therapy, significant efforts have been made to develop 
compounds for the treatment of brain disorders (Kazantsev and Thompson, 
2008). 
A variety of non-selective and selective HDAC inhibitors have been 
developed, both synthetically derived and from natural sources. Among the 
relatively non-selective HDAC inhibitors, trichostatin A (TSA) and 
suberoylanilide hydroxamic acid (vorinostat, also known as SAHA) inhibit 
most zinc-dependent HDACs and are permeable to the blood–brain barrier 
(BBB). The hydroxamate moiety of these compounds appears to bind the 
zinc ion at the HDAC active site to inactivate the enzyme. Sodium butyrate 
and 4-phenylbutyrate are fatty acid derivatives that inhibit most class I and II 
HDACs. However, butyrate does not appear to inhibit HDAC6 because the 
acetylation levels of α-tubulin, a substrate of HDAC6 (Hubbert et al., 2002), 
are unaffected by sodium butyrate treatment. Valproic acid, a fatty acid 
derivative with mood-stabilizing and anticonvulsant properties, is another 
HDAC inhibitor that binds to the active site of the enzymes; valproic acid 
inhibits class I and class IIa HDACs, but not class IIb (Gurvich et al., 2004). 
Butyrates and valproic acid are also known to readily cross the BBB (Butler 
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and Bates, 2006). Advances have been made to design more selective 
HDAC inhibitors. MS-275, a synthetic benzamide derivative, preferentially 
inhibits HDAC1, compared with HDAC2, 3 and 9, and has little or no activity 
against HDAC4, 6, 7, and 8. This drug also passes the BBB easily, can be 
administered orally, and appears to produce no severe side effects. Apicidin, 
a cyclic tetrapeptide, inhibits HDAC2 and 3 in the low nanomolar range and 
HDAC8 in the high nanomolar range, but does not affect HDAC1 or class II 
HDACs (Khan et al., 2008). Romidepsin (FK-228), another cyclic 
tetrapeptide, also potently inhibits HDAC1 and 2 (Itoh et al., 2008). Tubacin is 
a catalytic domain-targeting small molecule inhibitor showing high selectivity 
for HDAC6 and for the deacetylation of α-tubulin, a microtubule component 
(Haggarty et al., 2003). Suramin, a symmetric polyanionic naphthylurea, and 
its structural analogs, inhibit human NAD+-dependent class III SIRT1 and 
SIRT2 activity (Trapp et al., 2007). Nicotinamide, also known as niacinamide, 
is a precursor of NAD+ and a competitive class III HDAC inhibitor that can be 
given orally (Green et al., 2008). Table 1 lists the isoforms of these four 
classes of HDACs and their sensitivities to the key HDAC inhibitors 
discussed above (Chuang et al., 2009b). 
Despite the substantial progress made in the study of HDAC inhibitors, very 
little has so far been done regarding pharmacological manipulation of HAT 
activity. Amongst the very few HAT inhibitors, garcinol and curcumin were 
shown to penetrate cellular membranes and inhibit acetylation of histones in 
vivo (Balasubramanyam et al., 2003). 
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Table 1. HDAC isoforms and isoform-specific and nonspecific HDAC inhibitors (Chuang et al. 
2009)
 
 
I.B.7. Neuroprotection by HDAC Inhibition in Cellular Models 
HDAC inhibition has neuroprotective effects in both in vivo and in vitro 
models of brain disorders. One pioneering study noted that levels of the 
HATs CBP\p300 and histone protein acetylation were decreased during 
apoptosis induced by potassium deprivation of cultured primary cerebellar 
granule cells, and during signal activation of β-amyloid precursor protein 
(APP) in cultured primary cerebral cortical neurons from rodents (Rouaux et 
al., 2003). Moreover, overexpression of CBP\p300 protected these neurons 
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from proapoptotic insults. In cortical neurons, Ryu and colleagues showed 
that treatment with TSA, sodium butyrate, or vorinostat protected against 
glutathione depletion-induced oxidative stress; neuroprotection involved 
acetylation and activation of the DNA binding activity of Sp1 (Ryu et al., 
2003c). However, it is well known that some HDAC inhibitors, such as TSA, 
have basal toxicity and prolonged treatment at high doses often induces 
neuronal death, so compromising their neuroprotective effects (Jeong et al., 
2003). HDAC inhibitor-induced neurotoxicity could be partly due to 
‘derepression’ of genes involved in apoptosis including Bim and B-myb 
(Biswas et al., 2005). In fact, Langley and colleagues found that a two-hour 
pulse treatment with TSA sufficed to rescue cortical neurons from oxidative 
stress without obvious toxicity; protection was associated with transcriptional 
activation of the cell-cycle inhibitor p21waf1\cip (Langley et al., 2008). 
Glutamate-induced excitotoxicity has been implicated in the pathophysiology 
of many neurodegenerative and neuropsychiatric diseases; these include 
stroke, Huntington’s disease, amyotrophic lateral sclerosis, spinal cord and 
traumatic brain injury, cerebellar degeneration and possibly Alzheimer’s 
disease, Parkinson’s disease and mood disorders. Notably, Leng and 
Chuang demonstrated that valproic acid, 4-phenylbutyrate, or TSA treatment 
protected against glutamate-induced excitotoxicity in brain, with concomitant 
transcriptional activation and induction of α-synuclein, a presynaptic protein 
of unknown function. Recent experiments demonstrate that overexpression 
of endogenous α-synuclein plays a neuroprotective role; this appears to 
involve upregulation of the cytoprotective protein B-cell lymphoma 2 (Bcl-2) 
but downregulation of Ube2n, a proapoptotic, ubiquitin-conjugating enzyme. 
A subsequent study showed that α-synuclein protected cerebellar granule 
cells from 6-dihydroxydopamine-induced death. It appears that α-synuclein is 
neuroprotective in the cytoplasm, but becomes neurotoxic once translocated 
to the nucleus, where it inhibits HAT activity (Kontopoulos et al., 2006; Leng 
and Chuang, 2006; Monti et al., 2007). A more recent study found that 
valproic acid and other class I and II HDAC inhibitors (e.g. sodium butyrate, 
4-phenylbutyrate, and TSA) potentiated these neuroprotective effects against 
excitotoxicity, when used in conjunction with lithium, another mood stabilizer 
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with a robust neuroprotective profile (Feng et al., 2008). Taken together, the 
evidences suggest that HDAC inhibitors induce the expression of multiple 
downstream targets that might work collectively to elicit neuroprotective 
effects. Furthermore, HDAC inhibitors increase the expression of 
neurotrophins, molecules that play prominent roles in neuronal development, 
synaptic plasticity, and neuronal survival. For instance, Yasuda et al. found 
that brain-derived neurotrophic factor (BDNF) was induced in rat cortical 
neurons by treatment with valproic acid, sodium butyrate or TSA (Yasuda et 
al., 2009). Hong and colleagues found that both BDNF and glial cell line-
derived neurotrophic factor (GDNF) were induced by class I and II inhibitors 
in primary cultures of astrocytes from rat midbrain (Chen et al., 2006; Wu et 
al., 2008; Lin et al., 2011). Considerable previous studies have reported that 
HDAC inhibitors exerted neuroprotective effects by preventing microglia 
activation and anti-neuroinflammatory effects in some central nervous system 
(CNS) diseases (Cao et al., 2013). The anti-inflammatory effects of HDAC 
inhibitors were also found in an animal model of cerebral ischemia. Taken 
together, the in vitro studies demonstrate that HDAC inhibitors exert their 
neuroprotective effects through multiple mechanisms and that, in addition to 
neurons, glia are also targets of HDAC inhibition and neuroprotection 
(Chuang et al., 2009b). 
 
I.B.8. HDAC Inhibition in Animal Models of Neurodegenerative 
Disorders 
 
I.B.8.1. Huntington’s Disease (HD) 
HD is an inherited, autosomal-dominant fatal neurodegenerative disease 
characterized anatomically by a predominant loss of striatal medium-sized 
spiny neurons and cortical neurons, and clinically by hyperkinetic involuntary 
movement, cognitive impairment and memory loss, as well as by psychosis 
and emotional deterioration. The genetic mutation responsible for HD is an 
expansion of a CAG trinucleotide repeat encoding polyglutamine (polyQ) in 
the first exon of the huntingtin (HTT) gene. Transcriptional dysregulation 
plays a central role in the pathogenesis\pathophysiology of HD (Sugars and 
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Rubinsztein, 2003; Hodges et al., 2006). For example, HTT with an 
expanded polyQ repeat has been shown to interact with and impair 
neuroprotective transcription factors, such as Sp1 and its co-activator 
TAFII130 (Hahnen et al., 2008). Importantly, a very recent report by Jeong 
and colleagues showed that HTT was acetylated at K444 by the HAT, CBP 
(Jeong et al., 2009). Enhanced K444 acetylation facilitated the trafficking of 
mutant HTT into autophagosomes for degradation and reduced the 
neurotoxicity of mutant HTT both in primary neuronal cultures and in a C. 
elegans HD model. These findings identify acetylation of HTT as a new 
mechanism for clearing accumulated HTT protein and suggest that increased 
HTT acetylation is a potential target for HDAC inhibition to elicit 
neuroprotective effects in HD. Using R6\2 mice, a known animal model of 
HD, Ferrante and colleagues reported that sodium butyrate treatment 
decreased the neurodegenerative phenotype and improved survival 
(Ferrante et al., 2003). Moreover, it has been suggested that the 
pathophysiology of HD is coupled intimately to deficiency of both BDNF and 
HSP70 in affected brain regions (Zuccato et al., 2001). Because the 
expression of both BDNF and HSP70 is regulated by class I and II HDAC 
inhibitors, it is conceivable that restoring BDNF and HSP70 to their normal 
levels contributes to the beneficial effects of HDAC inhibition in various HD 
models. In this context, it is notable that vorinostat and TSA increase 
vesicular transport of BDNF by inhibiting HDAC6, thereby increasing tubulin 
acetylation and compensating for the transport deficit in HD (Dompierre et al., 
2007). However, the role of HDAC6 in HD pathology is clearly complex – for 
example, HDAC6-dependent retrograde transport on microtubules is crucial 
for the autophagic degradation of aggregated HTT (Iwata, A., 2005) and 
HDAC6 is therefore likely to be neuroprotective in this role. Further, 
expression of HDAC6 rescues polyQ-induced neurodegeneration associated 
with dysfunction of the ubiquitin–proteasome system in a fly model of spino-
bulbar muscular atrophy (Pandey et al., 2007). The dual roles of HDAC6 in 
neurodegeneration and neuroprotection complicate the application of this 
subtype-specific inhibition in treating polyQ-induced neurodegenerative 
diseases. 
Introduction - Epigenetics  
 
- 22 - 
   
I.B.8.2. Amyotrophic Lateral Sclerosis (ALS) 
ALS is an adult-onset neurodegenerative disease characterized by 
progressive loss of motor neurons in the brain, brain stem, and spinal cord; 
these lead to generalized weakness, muscle atrophy, paralysis, and eventual 
mortality within five years of disease onset. Most ALS cases occur 
sporadically, with only about 10% of patients being categorized as having a 
familial form. Of these, approximately 20% are attributed to gain-of-function 
mutations in the gene encoding Cu\Zn superoxide dismutase1 (SOD1), a key 
antioxidant enzyme. Mice expressing mutant Cu\Zn SOD1 exhibit ALS-like 
phenotypes, including the formation of intracellular aggregates of SOD1 in 
the brain and spinal cord, behavioral abnormalities and premature death. 
Because transcriptional dysregulation may play a role in the pathophysiology 
of ALS, the effects of HDAC inhibitors have been examined in transgenic 
ALS mouse models. Using SOD1\G93A transgenic mice, Ryu and colleagues 
injected 4-phenylbutyrate starting before or shortly after symptom onset; this 
resulted in extended survival and improved pathological phenotypes (Ryu et 
al., 2005). Valproic acid treatment of SOD1 mutant mice had variable effects 
on disease symptom onset, duration, and survival. For instance, pre- or post-
symptomatic valproic acid treatment in drinking water increased lifespan, but 
pre-symptomatic treatment had no effect on the onset of motor symptoms in 
G93A mice (Sugai et al., 2004). More recently, Feng et al. reported that 
valproic acid treatment of G93A mice had small, but significant, beneficial 
effects on motor dysfunction onset, motor deficits and survival time. In the 
latest study, combined treatment with valproic acid and lithium produced 
greater and more consistent benefits than valproic acid alone in delaying the 
onset of disease symptoms, prolonging lifespan, and decreasing neurological 
deficits (Feng et al., 2008). These and other studies highlight the potential 
effectiveness of combination treatments for ALS patients.  
 
I.B.8.3. Spinal Muscular Atrophy (SMA) 
SMA is an autosomal-recessive inherited motor neuron disease caused by 
degeneration of a-motor neurons in the anterior horn of the spinal cord and is 
characterized by weakness and atrophy of voluntary muscles. The genetic 
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basis of SMA, a leading hereditary cause of infant mortality, is homozygous 
deletion of the SMN1 gene on chromosome 5q13, that encodes the full-
length survival motor neuron protein. A related gene located within the same 
chromosomal locus, SMN2, is ubiquitously expressed, but encodes an 
unstable SMN protein lacking C-terminal residues. Although SMA patients 
lacking SMN1 carry at least one copy of SMN2, the amount of functional 
SMN protein produced by SMN2 is insufficient to combat progressive motor 
neuron degeneration. Disease severity appears to be inversely correlated 
with SMN2 gene copy number and SMN expression, suggesting that SMN2 
is a potential therapeutic target. A number of HDAC inhibitors increase SMN2 
mRNA and protein levels in vitro, including sodium butyrate (Chang et al., 
2001), 4-phenylbutyrate (Andreassi et al., 2004), valproic acid (Sumner et al., 
2003), M344, vorinostat (Hahnen et al., 2006), TSA and romidepsin (FK-228) 
(Avila et al., 2007). Interestingly, the SMN2 promoter associates with HDAC1 
and HDAC2, but not with HDAC3–5 (Kernochan et al., 2005), indicating that 
different HDAC isoforms play selective roles in regulating SMN gene 
expression. Chang and colleagues provided the first evidence that 
administering sodium butyrate to a transgenic mouse model of SMA (SMN1-
\-SMN2), increased SMN protein expression, combated clinical symptoms, 
and increased their lifespan (Chang et al., 2001). Using a similar mouse 
model, Tsai and colleagues showed that oral administration of valproic acid 
in drinking water improved motor function, promoted neuromuscular junction 
formation and also suppressed spinal motor neuronal degeneration and 
muscular atrophy. The beneficial effects of valproic acid were associated with 
elevated levels of SMN mRNA and protein in spinal tissues, as well as 
increased levels of the anti-apoptotic proteins Bcl-2 and Bcl-XL (Tsai et al., 
2008). 4-phenylbutyrate and valproic acid treatment increased SMN mRNA 
and protein in leukocytes of SMA patients and improved patients’muscle 
power (Brahe et al., 2005; Brichta et al., 2006). It should be noted that the 
beneficial effects of valproic acid and butyrate in both preclinical and clinical 
studies of SMA are limited. Future SMA studies using other HDAC inhibitors, 
notably class III inhibitors, seem warranted. Combinatorial treatment with an 
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HDAC inhibitor in conjunction with another drug exhibiting different actions 
would also be a rational approach. 
 
I.B.8.4. Parkinson’s Disease (PD) 
PD is a prevalent neurodegenerative disease characterized by a relatively 
selective loss of dopaminergic neurons, predominantly in the substantia 
nigra. Most cases of PD occur sporadically. An established model of PD 
involves treatment of mice with the classical dopaminergic toxin, 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP). Pioneering work by Beal and 
colleagues (Gardian et al., 2004), showed in this model that administration of 
phenylbutyrate significantly attenuated both dopamine depletion and loss of 
substantia nigra neurons expressing the dopamine biosynthetic enzyme 
tyrosine hydroxylase. Using a related dopaminergic toxin, 1-methyl-4-
phenylpyridinium (MPP+), in an in vitro model of midbrain neuron–glia 
cocultures, Hong and colleagues found that MPP+-induced death of 
dopaminergic neurons could be prevented by treatment with valproic acid, 
sodium butyrate, or TSA, as demonstrated by marked increases in dopamine 
uptake and the number of neurons staining positive for tyrosine hydroxylase 
(Chen et al., 2006; Wu et al., 2008). Mutations of a number of targets, 
including the presynaptic protein α-synuclein, have been linked to familial 
forms of PD. One study reported that nuclear α-synuclein binds histones to 
inactivate HATs including CBP, p300 and P\CAF, causing histone 
hypoacetylation and apoptosis in human neuroblastoma cells. By contrast, 
cytoplasmic accumulation of α-synuclein is neuroprotective both in cultured 
cells and in a transgenic Drosophila model of PD (Kontopoulos et al., 2006). 
More recently, Outeiro and colleagues reported that AGK2, a specific 
inhibitor of SIRT2, increased α-tubulin acetylation with the formation of large 
α-synuclein inclusions, and was able to rescue dopaminergic neurons both in 
vitro and in Drosophila PD model (Outeiro et al., 2007). Together, these 
findings suggest that both zinc-dependent HDACs, as well as SIRT2, are 
potential targets for therapeutic intervention in PD. 
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I.B.8.5. Alzheimer’s Disease (AD) 
AD is the fourth most common cause of death in the USA and affects ~50% 
of the population over 85 years of age in industrialized countries. Clinically, 
the disease is characterized by progressive memory loss and personality 
changes, ultimately leading to dementia. Its neuropathological hallmarks 
include accumulation of extracellular β-amyloid (Aβ), an aberrant processing 
product of normal APP, and intracellular neurofibrillary tangles resulting from 
hyperphosphorylation of Tau protein. A follow-up study by Guan et al. 
convincingly demonstrated that mice overexpressing HDAC2, but not 
HDAC1, exhibit decreased dendritic spine density, synaptic number and 
synaptic plasticity, and impaired memory formation (Guan et al., 2009). 
Conversely, Hdac2 knockout mice show memory improvement. Further, 
HDAC2 regulates synaptic formation and plasticity in the mouse 
hippocampus and binds to promoters of a spectrum of genes involved in 
neuronal activity, synaptic formation and plasticity. The memory impairment 
in mice overexpressing HDAC2 was ameliorated by treatment with the HDAC 
inhibitor vorinostat. These findings underscore the involvement of chromatin 
modification by HDAC2 in regulating synaptic plasticity and memory 
formation. In the Tg2576 mouse model of AD, daily injections of 4-
phenylbutyrate reversed spatial memory deficits by normalizing Tau 
hyperphosphorylation in the hippocampus, but without affecting Aβ levels 
(Barrett and Wood, 2008). In the APP23 transgenic mouse model of AD, 
daily injections with a relatively low dose of valproic acid (30 mg\kg, i.p.) 
robustly reduced Aβ plaque number and improved memory deficits when 
administered early (starting at seven months) (Qing et al., 2008). In another 
study, nicotinamide, a class III HDACs inhibitor, induced a chronic but low-
level, increase in endogenous p25, which surprisingly was linked to improved 
learning and memory. Although nicotinamide could exhibit its beneficial 
effects through both sirtuin-dependent and -independent mechanisms, these 
results suggest that class III HDACs are involved in the pathology of AD, and 
that oral nicotinamide potentially might prove useful as a treatment for this 
disease. 
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I.B.8.6. Stroke 
Stroke, an acute neurological\neurodegenerative disease, is the third leading 
cause of death in the USA. Most stroke cases are caused by cerebral 
ischemia. In a middle cerebral artery occlusion (MCAO) stroke model, 
reduced bulk histone acetylation was found at Lys residues in the ischemic 
brain of rats or mice; these changes were restored by treatment with HDAC 
inhibitors, with a concomitant decrease in infarct volume (Faraco et al., 
2006). In a rat MCAO model, Chuang and colleagues showed that post-insult 
treatment with valproic acid, sodium butyrate or TSA also improved 
behaviors (Ren et al., 2004; Kim et al., 2007b). Recently, neuroprotection 
was reproduced, by Lanzillotta et al., in mice subjected to MCAO and treated 
with the new class I HDAC inhibitor, MS-275 (20 μg\kg and 200 μg\kg) or 
resveratrol (6800 μg\kg), individually. Notably, the administration of lowest 
doses of MS-275 (2 μg\kg) and resveratrol (68 μg\kg) synergistically reduced 
infarct volume and neurological deficits. Importantly, the treatment was 
effective even when administered 7 h after the stroke onset (Lanzillotta et al., 
2012). Moreover, in the study of Cao et collegues, they evaluated the 
neuroprotective potential of the class I HDAC inhibitor, MS-275, on 
behavioral performance and histological outcome of acute neuronal 
degeneration (Cao et al., 2013). In addition, administration of 4-
phenylbutyrate in mice subjected to hypoxia–ischemia protected against 
endoplasmic reticulum (ER) stress (Kim et al., 2007b), evidenced by 
decreased eIF2a phosphorylation and expression of the eIF2a-regulated 
proapoptotic protein CHOP. It is increasingly recognized that 
neuroinflammation plays a causative role in neurodegeneration following 
ischemic injury. Kim et al. demonstrated that post-insult treatment with 
valproic acid or sodium butyrate suppressed permanent MCAO-induced 
activation of microglia and monocytes\macrophages and proinflammatory 
iNOS and COX-2 overexpression (Kim et al., 2007a). Treatment with HDAC 
inhibitors also markedly inhibited ischemia-induced p53 overexpression and 
superinduced heat shock protein 70 (HSP70) in the ischemic brain. It is likely 
that superinduction of endogenous HSP70 by HDAC inhibition contributes to 
these anti-inflammatory effects. In support, one recent study noted that 
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HSP70 overexpression inactivated NF-kB by stabilizing a complex of 
HSP70–IkBa–NF-kB in a mouse MCAO model (Zheng et al., 2008). The 
expression of cytoskeletal proteins has also been implicated in 
neuroprotection by HDAC inhibition under ischemic conditions. For instance, 
HDAC inhibition upregulated gelsolin, a protein involved in actin filament 
organization, and by this route contributed to neuroprotection from ischemic 
brain injury (Yildirim et al., 2008; Zheng et al., 2008). In addition, valproic acid 
was neuroprotective in an intracerebral hemorrhagic model of stroke by 
HDAC inhibition and transcriptional activation, and displayed anti-
inflammatory actions by down-regulating proinflammatory factors including 
Fas-L, IL-6, and MMP-9 (Sinn et al., 2007). The identity of the HDAC 
isoform(s) involved in HDAC inhibitor-mediated neuroprotection remains 
unclear. However, from the related cardiac field, it is noteworthy that 
knockdown of HDAC4 reduced infarct size following myocardial ischemia-
induced reperfusion injury (Chuang et al., 2009b). 
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I.C. SODIUM CALCIUM EXCHANGER 
I.C.1. State of Art of Na+\Ca2+ Exchanger 
The Na+\Ca2+ exchanger (NCX) consists of 9 transmembrane segments that 
can mediate Ca2+ and Na+ fluxes across the plasma membrane (Blaustein & 
Lederer, 1999) (Fig. 4). NCX was discovered and characterized in the late 
1960s, when Baker et al. (Baker et al., 1969), Reuter and Seitz (Reuter and 
Seitz, 1968), and Martin and De Luca (Martin and DeLuca, 1969) realized the 
presence of countertransport mechanism that exchanged Na+ and Ca2+ ions 
across the plasma membrane of different excitable and non excitable cells. 
However, the most crucial advancement in NCX research was made in 1988 
(Philipson et al., 1988) and 1990 (Nicoll et al., 1990) when Philipson and his 
colleagues purified and cloned the first isoform of this antiporter: NCX1. 
Remarkably, few years later, the same group cloned NCX2 (Li et al., 1994) 
and NCX3 (Nicoll et al., 1996), two isoforms selectively expressed in the 
brain and in the skeletal muscle. 
 
 
 
Figure 4. Molecular topology of NCX (Annunziato et al., 2004). 
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The regulation of intracellular concentration of Ca2+ and Na+ ions in excitable 
cells is a relevant physiological phenomenon that maintains cellular 
homeostasis. The Na+\Ca2+ exchanger, in parallel with selective ion channels 
and ATP-dependent pumps, maintains the physiological cytosolic 
concentrations of these ions (Blaustein and Lederer, 1999). Depending on 
the intracellular concentrations of Ca2+ [Ca2+]i, and Na
+, [Na+]i, NCX can 
operate either in the forward mode, coupling the uphill extrusion of Ca2+ to 
the influx of Na+ ions, or in the reverse mode, mediating the extrusion of Na+ 
and the influx of the Ca2+ ions (Blaustein and Lederer, 1999; Philipson and 
Nicoll, 2000). The stechiometry of NCX is generally accepted to be three Na+ 
ions\one Ca2+ ion; however, at a later time, in addition to the major 3:1 
transport mode, it has been demonstrate that ion flux ratio can vary from 1:1 
to a maximum of 4:1, depending on [Na+]i and [Ca
2+]i (Fujioka et al., 2000; 
Kang and Hilgemann, 2004).  
 
I.C.2. Molecular Biology of NCX and its Distribution 
The Na+\Ca2+ exchanger belongs to the superfamily of membrane proteins 
comprising the following members:  
1. the NCX family, which exchanges three Na+ ions for one Ca2+ ion or 
four Na+ ions for one Ca2+ ion depending on [Na+]i and [Ca
2+]i (Fujioka 
et al., 2000; Kang and Hilgemann, 2004) 
2. the Na+\Ca2+ exchanger K+-dependent family, which exchanges four 
Na+ ions for one Ca2+ plus one K+ ion (Lytton et al., 2002) 
3. the bacterial family which probably promotes Ca2+\H+ exchange 
(Cunningham and Fink, 1996)  
4. the nonbacterial Ca2+\H+ exchange family, which is also the Ca2+ 
exchanger of yeast vacuoles (Pozos et al., 1996) 
5. the Mg2+\H+ exchanger, an electrogenic exchanger of protons with 
Mg2+ and Zn2+ ions (Shaul et al., 1999)  
These membrane proteins are all peculiarly characterized by the presence of 
α-repeats, the regions involved in ion translocation. About the NCX family, 
three dominant genes coding for the three different NCX1, NCX2 and NCX3 
proteins have been identified in mammals. These three genes appear to be 
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dispersed, since NCX1, NCX2 and NCX3 have been mapped in mouse 
chromosomes 17, 7, and 12, respectively (Nicoll et al., 1996). At the post-
transcriptional level, at least 17 NCX1 and 4 NCX3 proteins are generated 
through an alternative splicing of the primary nuclear transcripts (Quednau et 
al., 1997). These variants arise from a region of the large intracellular f loop, 
are encoded by six small exons defined A to F, and are used in different 
combinations in a tissue-specific manner (Lee et al., 1994). To maintain an 
open reading frame, all splice variants must include either exon A or B, which 
are mutually exclusive. Excitable tissues, such as those of the brain and 
heart, are usually characterized by the presence of exon A, whereas kidney, 
stomach, and skeletal muscle tissues comprise NCX with exon B (Quednau 
et al., 1997). 
NCX1 is composed of 938 aminoacids, in the canine heart, having a 
theoretical molecular mass of 120 KDa and containing nine transmembrane 
segments (TMS). NCX1 amino-terminus is located in the extracellular space, 
whereas the carboxyl terminus is located intracellularly (Fig. 4). The nine 
transmembrane segments can be divided into an N-terminal hydrophobic 
domain, composed of the first five TMS (1-5), and into a C-terminal 
hydrophobic domain, composed of the last four TMS (6-9). These two 
hydrophobic domains are important for the binding and the transport of ions. 
The first (1-5) TMS are separated from the last four (6-9) TMS through a 
large hydrophilic intracellular loop of 550 amino acids, named the f loop 
(Nicoll et al., 1999). Although the f loop is not implicated in Na+ and Ca2+ 
translocation, it is responsible for the regulation of NCX activity elicited by 
several cytoplasmic messengers and transductional mechanisms, such as 
Ca2+ and Na+ ions, NO, phosphatidylinositol 4,5 bisphosphate (PIP2), protein 
kinase C (PKC), protein kinase A (PKA), and ATP. In the center of the f loop, 
a region of approximately 130 amino acids in length has been reported to 
exert a Ca2+ regulatory function. This region is characterized by two Ca2+ 
binding domain (CBD1 and CBD2) that undergo conformational changes 
upon binding of Ca2+ and look very similar in the Ca2+ bound form, whereas in 
the absence of Ca2+, the domains show dramatic structural differences. 
CBD1 binds Ca2+ with Kd values of 120 and 240 nM, whereas the respective 
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values of CBD2 are 820 nM and 8,6 µM (Fig. 5) (Hilge et al., 2006). At the N-
terminal end of the f loop near the membrane lipid interface, an autoinhibitory 
domain, rich in both basic and hydrophobic residues, named exchange 
inhibitory peptide (XIP) (Matsuoka et al., 1997), has been identified. The f 
loops also characterized by alternative splicing sites named β1-repeat and 
β2-repeat. These β-repeats are characterized by similar regions comprising 
60 to 70 amino acids for which no functional role has been proposed 
(Hilgemann, 1990). 
 
 
Figure 5.Ca
2+ 
binding in CBD1 and CBD2 domains. (Hilge et al., 2006) 
 
The NCX protein aminoacid sequence found between TMS2 and TMS3 is 
called α-1 repeat, whereas the one found between TMS7 and TMS8 is 
named α-2 repeat. Both these regions are located on the opposite site of the 
membrane and include two segments composed of 12 and 9 highly 
conserved residues separated by a non conserved segment of 18 to 20 
amino acids (Nicoll et al., 2002). Since the putative α-helices of the α-repeats 
are amphipathic, the hydrophilic faces of these helices may form a portion of 
the ion translocation pathway (Nicoll et al., 1996).  
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Interestingly, NCX2 and NCX3 have been found only in the brain and in the 
skeletal muscle. These two gene products consist of 921 and 927 amino 
acids and are characterized by molecular masses of 102 and 105 KDa, 
respectively. In addition, NCX2 displays a 65% sequence identity with NCX1, 
whereas NCX3 possesses a 73% sequence identity with NCX1 and 75% 
sequence identity with NCX2 (Nicoll et al., 1996). All three NCX gene 
products share the same membrane topology.  
In the central nervous system (CNS), the Na+\Ca2+ exchanger plays a 
fundamental role in controlling the changes in the intracellular concentrations 
of Na+ and Ca2+ ions. These cations are known to regulate neurotransmitter 
release, cell migration and differentiation, gene expression, and 
neurodegenerative processes.  
 
I.C.3. Regulation of Na+\Ca2+ Exchanger Activity 
Several factors are involved in the regulation of Na+\Ca2+ exchanger activity: 
the intracellular pH; metabolic related compounds, ATP, PA, PIP2, PKA, and 
PKC; redox agents, hydroxyl radicals, H2O2, dithiothreitol (DTT), O2
- ,Fe3+, 
Fe2+, Cu2+, OH, glutathione reduced (GSH), and glutathione oxidized 
(GSSG); and the gaseous mediator, NO. The site level at which [Ca2+]i 
regulates NCX activity is different from the one required for Ca2+ transport 
(Levitsky et al., 1994). The removal of intracellular Ca2+ ions completely 
blocks NCX activity (Philipson and Nicoll, 2000). The location of such 
regulatory site has been identified in the 134-amino acid region, situated in 
the center of the f loop. In addition to intracellular Ca2+ regulatory site, an 
increase in [Na+]i can also regulate the Na
+\Ca2+ exchanger. In particular, 
when intracellular Na+ increases, it binds to the transport site of the 
exchanger molecule, and after an initial fast outward the Na+\Ca2+ current, an 
inactivation process occurs (Hilgemann et al., 1992). This inactivation 
process, very similar to the phenomenon occurring in voltage-dependent 
ionic channels, is named Na+-dependent inactivation. The region of the 
intracellular f loop, in which this regulatory site is located, has been identified 
in a 20-aminoacid portion of the N-terminal part of the loop named XIP 
(Matsuoka et al., 1997). Regarding on the mechanism by which XIP inhibits 
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NCX activity, it has been proposed that when the XIP-binding site is ligand-
occupied, a conformational change is induced in C-terminal portion of the f 
loop, thus resulting in the inhibition of the ion transport (Li et al., 1991). XIP is 
provided with relevant pharmacological implications. In fact, those exogenous 
peptides, having the same amino acid sequence as XIP, act as potent 
inhibitors of NCX activity (Annunziato et al., 2004; Pignataro et al., 2004). 
Interestingly, Ca2+ ions, at low micromolar concentrations, binding its 
regulatory site, decrease the extent of this Na+-dependent inactivation. In 
fact, mutations in the Ca2+ regulatory binding site alter the activation and 
inactivation kinetics of exchange currents by modulating Na+-dependent 
inactivation (Matsuoka et al., 1995).  
H+ strongly inhibits NCX activity under steady-state conditions (Doering and 
Lederer, 1993). The action exerted by H+ ions is pathophysiologically relevant 
with regards to brain and heart ischemia. In fact, when intracellular H+ and 
Na+ ion homeostasis is deregulated, the anoxic conditions resulting in these 
cells may selectively interfere with the activity of the different NCX gene 
products.  
ATP may increase the activity of the exchanger in a number of ways. Firstly, 
ATP directly participates in the NCX molecule phosphorylation process by 
PKA and PKC (Caroni and Carafoli, 1983). Secondly, it increases PIP2 
production. This mechanism of activation is related to the relevant PIP2 
influence on Na+-dependent inactivation of NCX. In fact, PIP2 directly 
interacts with the XIP region of the exchanger, thus eliminating its inactivation 
and stimulating NCX function (Hilgemann and Ball, 1996). Finally, by 
activating G-protein-coupled receptors, via endogenous and exogenous 
ligands, ATP can stimulate NCX activity through the pathway involving PKC 
or PKA activation (DiPolo and Beaugé, 1998). The mechanism underlying the 
phosphorylating effect on the exchanger seems to be related to an increase 
in its affinity for both internal Ca2+ and external Na+ and to a decrease in its 
inhibition by internal Na+. In addition, ATP cellular depletion inhibits NCX1 
and NCX2, but does not affect NCX3 activity (Secondo et al., 2007a).  
Moreover, phosphoarginine (PA) can stimulate NCX activity. In particular, PA 
present in millimolar concentrations in the cytosol, activates Na+\Ca2+ 
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exchanger function in the forward mode of operation by intracellular Mg2+- 
and Ca2+-dependent way (Di Polo et al., 2004).  
Several groups of investigators also have found that NCX is sensitive to 
different combinations of redox agents (Amoroso et al., 2000; Santacruz-
Toloza et al., 2000). In particular, the stimulation of the exchanger activity 
requires the combination of a reducing agent with an oxidizing agent. The 
effects of both agents are mediated by metal ions. The antiporter’s sensitivity 
to changes in the redox status can assume particular relevance during 
oxidative stress. In fact, in this condition, the modulation of reactive oxygen 
species (ROS) could affect the transport of Na+ and Ca2+ ions through the 
plasma membrane (Santacruz-Toloza et al., 2000). 
The ubiquitous gaseous mediator NO seems to be involved in the modulation 
of NCX activity. In fact, there are several evidences that NO, released by NO 
donors, is able to stimulate NCX in the reverse mode of operation in neuronal 
preparations and astrocytes. By contrast, in C6 glioma cells, the stimulatory 
action on NCX reverse mode of operation, elicited by the sodium 
nitroprusside (SNP), is not elicited by NO release but by the presence of iron 
in SNP molecule (Amoroso et al., 2000). In addition, the relationship between 
the constitutive form of nitric oxide synthase (NOS) and NCX has recently 
been demonstrated. Indeed, heat stress by inducing NOS phosphorylation 
causes NOS complexation with NCX, thus decreasing its activity (Kiang et 
al., 2003). 
 
I.C.4. Pharmacological Modulation of Na+\Ca2+ Exchanger Activity: 
Inhibitors and Activators 
A great deal of interest has been devoted to the pharmacological modulation 
of NCX. The reasons for this enormous interest lay in the hope of finding 
clinically effective drugs for those pathophysiological conditions in which a 
stimulation or an inhibition of the NCX might have achieved beneficial effects. 
A lot of drugs that could specifically modulate NCX activity, have been 
developed.  
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I.C.4.1. Inhibitors 
1. A great interest has been oriented to the endogenous exchanger 
inhibitor peptides. Since it was demonstrated that a 20-amino acid 
sequence of the intracellular f loop of the exchanger molecule, XIP, 
played an autoinhibitory function through an Na+-dependent 
inactivating mechanism and that the synthetic peptides with the same 
amino acid sequence could exert an inhibitory action on NCX function 
(Li et al., 1991; DiPolo and Beaugè, 1994), a great effort has been 
made to synthesize and to characterize the molecular pharmacology 
of different XIP analogs. XIP, an anphipathic molecule, potently 
inhibits Na+\Ca2+ exchanger activity in both modes of operation. Since 
XIP hardly penetrates the cell membrane because of its prevalent 
hydrophilia, a XIP bearing a molecule of glucose attached to the Tyr-6 
residue has recently been synthesized (Fig. 6). Interestingly, this Tyr-
6-glycosilated form of XIP, intracerebroventricularly infused in male 
rats bearing permanent middle cerebral artery occlusion (pMCAO), 
caused a dramatic increase in infarct volume (Pignataro et al., 2004). 
These results suggest that NCX plays a pivotal role in the 
mechanisms that lead to neuronal death under ischemic conditions. 
Therefore, a pharmacological modulation of its activity may represent 
one of the possible therapeutic strategies for stroke treatment. 
 
 
Figure 6. Structure of the 6-tyrosine glycosilated form of the exchange inhibitor peptide 
XIP (Annunziato et al., 2004). 
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2. As inhibitors of NCX activity, amiloride and its derivates have been 
used. In attempt to evaluate NCX activity, amiloride has been used as 
a probe to block NCX function (Sharikabad et al., 1997). However, two 
major drawbacks have limited its use. Firstly, micromolar 
concentrations are required for its NCX inhibitory activity; secondly, it 
lacks specifity, for it can also inhibit both the epithelial Na+ channel at 
micromolar concentrations and the Na+\H+ exchanger in the millimolar 
range. More recently, to overcome these hindrances, two classes of 
amiloride analogs have been developed. The compounds of first class 
have inhibitory effect on the epithelial Na+ channel and on the plasma 
membrane NCX, even though that display great affectiveness in 
inhibiting the Na+\H+ exchange in the 1 to 10 µM range (Amoroso et 
al., 1990; Taglialatela et al., 1990). The compounds of second class, 
having no inhibitory effect on the Na+\H+ exchanger, bear substituents 
on the terminal guanidine nitrogen atom and behave as specific 
inhibitors of the epithelial Na+ channels and NCX. Among these 
compounds, dimethyl-benzamylamiloride (DMB) has been shown to 
be a selective inhibitor of the Na+\Ca2+ exchanger in exitable cells, 
such as neurons, in which the kidney epithelial Na+ channels are not 
expressed (Taglialatela et al., 1990). In contrast, [N-(4-
chlorobenzyl)]2,4-dimethylbenzamyl (CB-DMB) appears to be the 
most specific inhibitor of NCX activity, for it has no inhibitory properties 
against the Na+\H+antiporter and the epithelial Na+ channels 
(Sharikabad et al., 1997). The amiloride derivatives are able to 
reversibly inhibit NCX activity either when the antiporter operates in 
the forward (Taglialatela et al., 1990) or in the reverse mode of 
operation (Amoroso et al., 1997). It was hypothesized that these 
derivatives act as Na+ analogs, interacting at an Na+-binding site on 
the carrier, presumably, the region to which the third Na+ binds, and 
reversibly tie up the transporter in an inactive complex (Kaczorowski et 
al., 1985). Because of their pharmacological properties, these 
amiloride derivative compounds have been shown to interfere with the 
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release of neurotransmitters from the brain, under both physiological 
and pathophysiological conditions. 
3. Bepridil is a diarylaminopropylamine derivate having multiple inhibitory 
effects on ionic currents, including the L-type (Yatani et al., 1986) and 
T-type Ca2+ currents (Cohen et al., 1992), the delayed-rectifier K+ 
current, the transient outward current (Berger et al., 1989), as well as 
the K+ current, activated by intracellular Na+ (Mori et al., 1998). In 
addition to these pharmacological properties, bepridil can also block 
NCX activity (Watanabe and Kimura, 2001). This inhibitory action is 
dependent on the mode of operation of the antiporter. In fact, NCX 
operating in the forward manner is more strongly inhibited than in the 
reverse mode of action. The site of action of bepridil may be located 
on the cytoplasmic side of the exchanger, since the intracellular 
treatment with trypsin attenuates its inhibitory action (Watanabe and 
Kimura, 2001). In in vivo models of ischemia, bepridil, by blocking 
NCX, enhances glial and neuronal injury elicited by pMCAO 
(Pignataro et al., 2004).  
4. KB-R7943, an isothiourea derivative, was identified by Shigekawa’s 
group (Iwamoto and Shigekawa, 1998), because they screened a 
compound library for the inhibition of Na+-dependent Ca2+ uptake. A 
particular feature of this compound is that it inhibits the antiporter with 
a different potency, depending on NCX mode of operation. In fact, 
when NCX operates in the forward mode, the IC50 value needed for 
NCX inhibition is much lower than the IC50 value needed for the 
inhibition of reverse mode of operation (Iwamoto et al., 1996). KB-
R7943 interacts with the exchanger molecule extracellularly at the α-2-
repeat, between the TMS7 and TMS8 of the exchanger (Iwamoto et 
al., 2001; Shigekawa et al., 2002). According to peculiar 
pharmacological properties, KB-R7943 has aroused a great deal of 
interest among investigators working on NCX activity. It has been 
demonstrated that KB-R7943, in rats bearing pMCAO, reduces infarct 
volume (Papa et al., 2003). This neuroprotective action of this 
compound does not seem the result of NCX blockade, since other 
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antiporter inhibitors, such as GLU-XIP, CB-DMB, and bepridil, do 
indeed aggravate brain injury (Tortiglione et al., 2002; Annunziato et 
al., 2004; Pignataro et al., 2004; Sirabella et al., 2009). To explain the 
neuroprotective effect of KB-R7943 in pMCAO, it should be noted that 
this drug is also able to produce a remarkable and long-lasting 
hypothermic effect (Pignataro et al., 2004), which itself exerts a 
relevant neuroprotective action in cerebral ischemia (Yanamoto et al., 
2001). In addition, recent reports have shown that KB-R7943, besides 
its peculiar NCX blocking properties, also exerts an inhibitory effect on 
several other ionic transport mechanisms, such as L-type VGCC. 
Moreover, this compound inhibits receptor-operated ion channels, 
such as NMDA (Matsuda et al., 2001) whose blockade may also lead 
to neuroprotective actions (Paule et al., 2003). 
5. In 2001, the newly synthesized ethoxyaniline derivative SEA0400, was 
reported as being the most potent NCX inhibitor available at the time 
(Matsuda et al., 2001). More recent studies, however, demonstrated 
that it was also able to interfere with Ca2+ movement across the cell 
membrane (Reuter et al., 2002). This compound, similarly to KB-
R7943, inhibits the antiporter’s Na+ efflux-Ca2+ influx mode of 
operation. However, at variance with the isothiourea derivative, it 
predominantly blocks NCX1, it has lower affinity for NCX2, and it has 
no effect on NCX3 (Iwamoto et al., 2004b).  
 
I.C.4.2. Activators 
The availability of pharmacological agents capable of stimulating the activity 
of NCX, either in the reverse or in the forward mode of operation, may 
represent a useful strategy to adopt in some pathophysiological conditions, 
such as cardiac or brain ischemia. The pharmacological stimulation of the 
antiporter could, in fact, contribute to the re-establishment of intracellular Na+ 
and Ca2+ ion homeostasis. 
1. Li+, a monovalent cation, is able to stimulate the Na+i-dependent Ca
2+ 
uptake of all three NCX gene products with low affinity. Its exent of 
stimulation is, however, somewhat smaller in NCX1 than in NCX2 and 
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NCX3 (Iwamoto and Shigekawa, 1998). Some groups of investigators 
have provided evidence that a long-term Li+ exposure robustly 
protects cultured cerebellar, cortical, and hippocampal rat neurons 
against glutamate-induced excitotoxicity (Nonaka et al., 1998), 
suppresses the protein and mRNA expression of the two pro-apoptotic 
factors p53 and BAX, and increases the antiapoptotic mediator Bcl-2 
(Chen and Chuang, 1999). However, the possible interplay between 
the activation of NCX and Li+ neurobenefical effect still remains to be 
demonstrated. 
2. As previously mentioned, changes in the redox state are capable of 
stimulating the NCX activity. It was proposed that these agents could 
activate the exchange activity by promoting thiol-disulfide interchange 
in the protein carrier (Reeves et al., 1986). More recently, the cysteine 
residues involved in this disulfide bond have been identified. However, 
the analysis of mutated exchangers has indicated that cysteines are 
not responsible for the stimulation of the exchanger activity induced by 
a mixture of redox agents (Fe-DTT). Therefore, it has been suggested 
that the stimulation of NCX by Fe-DTT is mainly due to the removal of 
the Na+-dependent inactivation process (Santacruz-Toloza et al., 
2000). 
Since redox changes in NCX activity have been implicated in several aspects 
of cell physiology and pathophysiology, it is possible to speculate that agents 
capable of stimulating NCX might constitute a possible therapeutic strategy in 
those pathological conditions in which oxidative stress is involved. In this 
regard, evidence that the stimulation of NCX activity by oxidant agent Fe3+ 
may exert a neuroprotective effect both in in vitro a and in in vivo models of 
hypoxia and ischemia has been provided. It has been demonstrated that 
SNP, by stimulating NCX activity through its K3Fe(CN)6 portion-containing 
iron, is able to significantly reduce cellular injury elicited by chemical hypoxia 
(Amoroso et al., 2000). That Fe3+ should be responsible for this SNP 
neuroprotective effect is demonstrated by the fact that deferoxamine, an iron 
ion chelator, reverses the neuroprotection. This neuroprotective effect of iron 
has recently been confirmed in rats bearing pMCAO. In fact, FeCl3, 
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intracerebroventricularly perfused after ischemia induction, has been shown 
to reduce the extension of brain infarct volume (Pignataro et al., 2004). 
Collectively, these results suggest that a stimulation of NCX activity during 
stroke might help neurons and glial cells to survive.  
 
I.C.5. Na+\Ca2+ Exchanger Intervention in Physiological Conditions  
The Na+\Ca2+ exchanger protein may play a relevant function in different 
neurophysiological conditions. In neuron, the level of NCX expression is 
particularly high in those sites where a large movement of Ca2+ ions occurs, 
as it happens at level of synapses (Canitano et al., 2002). In particular, 
during an action potential or after glutamate-activated channel activity, there 
is a large increase in cytosolic free Ca2+ concentration [Ca2+]cyt. Ca
2+ is 
removed from the contractile apparatus and sequestrated in the intracellular 
store by the sarcoplasmic reticulum (SR) Ca2+ (SERCA) pump and\or 
extrusion to the extracellular fluid (ECF). Ca2+ is extruded by the plasma 
membrane Ca2+ ATPase and by NCX. The Na+\Ca2+ exchanger becomes the 
dominant Ca2+ extrusion mechanism when [Ca2+]i is higher than 500nM, as it 
happens when a train of action potentials reaches the nerve terminal. It has 
been calculated that for these [Ca2+]i values (500nM), more than 60% of Ca
2+ 
extrusion is mediated by Na+\Ca2+ exchanger families. In addition, because 
the three NCX isoforms are differentially expressed in several CNS regions, it 
seems that each isoform may play a different functional role in distinct 
regions of the brain (Papa et al., 2003). Essentially, the primary function of 
NCX is to extrude Ca2+ from the cell, in the forward mode, using [Na+] 
gradient. However, under some physiologic conditions, such as the 
occurrence of an action potential or of spontaneous [Ca2+]i oscillations, NCX 
could revert its mode of operation, thus participating in endoplasmic reticulum 
(ER)-Ca2+ refilling. In fact, it has been demonstrated that spontaneous [Ca2+]i 
oscillations induced by inositol 1,4,5-triphosphate receptor stimulation might 
lead to the activation of non-selective cation channels, which causes Na+ 
influx into the junctional cytosol microdomains. This influx facilitates the 
entrance of Ca2+ through NCX working in the reverse mode (Fameli et al., 
2007). 
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I.C.6. Pathophysiological Implications of the Na+\Ca2+ Exchanger in CNS 
Functions 
The dysregulation of [Ca2+]i  and [Na
+]i homeostasis is involved in neuronal 
and glial injury, occurring in in vitro and in vivo models of hypoxia-anoxia and 
in several neurodegenerative diseases. In fact, during anoxic conditions, due 
to the compromission of the two plasmamembrane ATP-dependent pumps – 
Na+\K+ ATPase and Ca2+ ATPase – NCX assumes a relevant role in 
controlling the intracellular homeostasis of these two cations. The role played 
by NCX in neurons and glial cells involved in cerebral ischemia should be 
differentiated according to the anatomical regions involved in the ischemic 
pathological process. In particular, it is conceivable that, since in the 
penumbral region ATPase activity is still preserved, NCX may likely work in a 
forward mode; as a result, by extruding Ca2+ ions, the exchanger favors the 
entry of Na+ ions. Therefore, the inhibition of NCX in this area reduces the 
extrusion of Ca2+ ions, thus enhancing Ca2+-mediated cell injury. In contrast, 
in the ischemic core region, in which ATP levels are remarkably low and 
Na+\K+ ATPase activity is reduced, intracellular Na+ ions massively 
accumulate because of Na+\K+ ATPase failure. Hence, the intracellular Na+ 
loading promotes NCX to operate in the reverse mode as an Na+ efflux-Ca2+ 
influx pathway. Consistently, biochemical studies have clearly demonstrated 
that whereas NCX1 and NCX2 activity is strictly dependent on ATP levels, 
which are lowered during the development of brain ischemia, NCX3 is the 
only NCX gene product that is independent of ATP (Secondo et al., 2007b). 
In conclusion, the NCX pharmacological inhibition in this core region, further 
worsens the necrotic lesion of the surviving glial and neuronal cells as the 
loading of the intracellular Na+ increases (Pignataro et al., 2004). More 
specifically, according to the time step of the ischemic pathological process, 
in the early phase of neuronal anoxic insult, the Na+\K+-ATPase blockade 
increases [Na+]i, which in turn induces NCX to reverse its mode of operation. 
Although during this phase NCX causes an increase in [Ca2+]i, its effect on 
neurons appears beneficial for two reasons. First, by promoting Ca2+ influx, 
NCX favors Ca2+ refilling into the ER, which is depleted by anoxia followed by 
reoxygenation, thus allowing neurons to delay ER stress (Sirabella et al., 
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2009). Second, by eliciting the decrease in [Na+]i overload, NCX prevents cell 
swelling and death (Annunziato et al., 2007). Conversely, in the later phase 
of neuronal anoxia, when [Ca2+]i overload takes place, NCX forward mode of 
operation contributes to the lowering of [Ca2+]i, thus protecting neurons from 
[Ca2+]i-induced neurotoxicity (Annunziato et al., 2004). Furthermore, NCX is 
involved in some serious diseases characterized by a loss of ion 
homeostasis control, including Alzheimer’s disease, multiple sclerosis, and 
epilepsy (Craner et al., 2004; Ketelaars et al., 2004; Pannaccione et al., 
2012). Recently, experiments in ischemic rats treated with inhibitors of NCX 
activity or synthesis, together with experiments in knockout mice for the ncx1, 
ncx2 or ncx3 gene, have demonstrated that the blockade of NCX protein 
synthesis or activity worsens ischemic brain damage by dysregulating Na+ 
and Ca2+ homeostasis (Pignataro et al., 2004). Therefore, in recent years 
there has been great interest in the identification of new compounds capable 
of increasing NCX activity to limit the extension of ischemic brain damage. 
 
I.C.7. Neurounina-1: a Novel Compound That Increases Na+\Ca2+ 
Exchanger Activity 
Until a few years ago, only non-selective NCX activators have been reported 
to stimulate NCX activity, including lithium (Iwamoto and Shigekawa, 1998), 
redox agents (Reeves et al., 1986; Secondo et al., 2011), agonists of G-
protein-coupled receptors (Eriksson et al., 2001; Woo and Morad, 2001; 
Annunziato et al., 2004), diethylpyrocarbonate (Ottolia et al., 2001), 
concanavalin A, nerve growth factor and insulin (Makino et al., 1988; 
Formisano et al., 2008). Molinaro et al. obtained an activator of the NCX 
isoforms, modifying the structure of one of the most potent NCX inhibitors, 
SM-15811, thereby synthesizing a new compound, 7-nitro-5-phenyl-1-
(pyrrolidin-1-ylmethyl)-1H-benzo[e][1,4]diazepin-2(3H)-one, that they named 
neurounina-1. In their study, it was demonstrated that neurounina-1 is the 
first molecule that enhances NCX1 and NCX2 activity and also exerts a 
remarkable neuroprotective effect in stroke. It is noteworthy that neurounina-
1 displayed a potent and reversible stimulatory effect on NCX1 and NCX2 in 
both forward and reverse modes of operation, with an estimated EC50 in the 
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low nanomolar range (1- 0.1 nM). By contrast, this compound did not affect 
the activity of the NCX3 isoform in the range of 0.001 to 10 mM. It is 
noteworthy that the results obtained in vivo showed that the intraperitoneal 
administration of neurounina-1 in single doses ranging from 0.003 to 30 
mg\kg significantly reduced the infarct volume in a mouse model of tMCAO. 
Remarkably, neurounina-1 was effective even when administered up to 5 
hours after ischemia induction, a therapeutic window that, along with its 
viable route of administration, may have interesting clinical perspectives. 
Collectively, these results showed that neurounina-1 is provided with high 
potency for NCX1 and NCX2, a high lipophilicity index, low toxicity, and a 
remarkable neuroprotective effect in experimental model of cerebral 
ischemia, with a wide therapeutic window and easy route of administration 
(Molinaro et al., 2013). 
 
I.C.8. Transcriptional Regulation of ncx1 Gene in the Brain 
Although much research has focused on the mechanisms of regulation of 
ncx1 at the post-translational level, few studies have directly addressed the 
regulation of ncx1 expression at the transcriptional level. Specifically, little is 
known on the mechanisms responsible for the changes in ncx1 expression 
caused by a variety of signals such as glucocorticoids, growth factors, 
depolarization, Ca2+ influx, and adrenergic stimulation (Golden et al., 2000; Li 
et al., 2000; Smith and Smith, 1994) or occurring under physiological or 
pathophysiological conditions such as post-natal development (Gibney et al., 
2002) and cerebral ischemia (Boscia et al., 2006; Li et al., 2006; Lu et al. 
2002; Pignataro et al., 2004). ncx1 gene expression appears to be directed 
by three alternative regulatory regions, named heart (Ht), kidney (Kd), and 
brain (Br) promoters (Lee et al., 1994). These promoters include different 
binding sequences for several transcriptional factors that control the tissue-
specific expression of ncx1 in the heart, kidney and brain (Barnes et al., 
1997; Lee et al., 1994; Nicholas et al., 1998). Specifically, in cardiomyocytes, 
the expression of ncx1 is controlled by the Ht promoter that includes serum 
response factor (SRF), GATA-4, activator protein 1 (AP-1), and Nkx2.5 
binding sites (Nicholas and Philipson, 1999). In particular, the cardiac-
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specific homeodomain transcription factor Nkx2.5 induces the expression of 
ncx1 and enhances SRF-induced ncx1 gene transcription in neonatal 
cardiomyocytes (Muller et al. 2002). In kidney, the ncx1 expression is 
controlled by the Kd promoter region that includes a typical TATA box 
preceded by two tandem GATA elements, NF-Y binding site, and two 
CAAT\enhancer binding protein-like (C\EBP-like) sites. Furthermore, Kd 
promoter has two putative binding elements for CREB, one for the activating 
transcription factor (ATF) and one for AP-1. Although each of these 
transcriptional binding sites is not specific to the kidney, their unique 
combinations may lead to kidney-specific transcription regulation (Nicholas et 
al., 1998). 
Br ncx1 promoter is an ubiquitous GC-rich TATA-less promoter, giving rise to 
the majority of ncx1 transcripts in the brain. This region contains several 
putative binding sites for transcriptional factors including Specificity protein 1 
(Sp1), AP-1, AP-2, and nuclear factor kB (NF-kB). It has been hypothesized 
that Sp1 and NF-kB binding sites could be responsible for the ubiquitous 
transcription of ncx1 in all tissues, whereas the high level of expression of 
NCX1 in the brain could be dependent on AP-2 (Nicholas et al., 1998). 
Consistent with the hypothesis that the constitutive expression depends on 
Sp1 and NF-kB, the region spanning from 312 bp upstream the transcription 
start site (TSS) to 151 bp downstream the TSS of Br promoter, which 
contains the binding sites for these transcriptional factors, is sufficient to 
induce the expression outside the brain, in rat vascular smooth muscle cells 
(VSMC) (Scheller et al. 1998). To date, the promoter of ncx2 gene has not 
yet been identified, and moreover, no extensive data are available for its 
transcriptional regulation. On the other hand, it has been shown that ncx2 
expression is rapidly downregulated after membrane depolarization in a 
calcineurin-dependent manner, suggesting the possible involvement of the 
transcriptional factor CREB (Li et al. 2000). The promoter of ncx3 is located 
immediately upstream of first exon (Gabellini et al., 2003) and includes 
binding sites for AP-1, AP-2, CREB, downstream regulatory element 
antagonist modulator (DREAM), Egr-1, KROX24, MyoD, GATA2\3, and Sp1. 
Two of these transcription factors, CREB and DREAM, seem to be the most 
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important regulators of ncx3 gene transcription in response to changes in the 
intracellular concentrations of Ca2+ and cAMP (Gabellini et al. 2003;Gomez-
Villafuertes et al. 2005). 
During the last 10 years, many evidences demonstrated that NCX1 exerts a 
neuroprotective activity in experimental models of stroke, and suggested that 
ischemic neurons could be rescued from cell death by enhancing the 
expression or the activity of NCX1 isoform with neurotrophic factors or 
neuroprotective drugs (Annunziato et al., 2004; Pignataro et al., 2004; Boscia 
et al., 2006; Secondo et al., 2007a; Sirabella et al., 2009). Such a therapeutic 
approach appears rational also considering that ncx1 gene expression was 
found to be downregulated during stroke by unknown mechanisms (Boscia et 
al., 2006). Recently there is a growing interest in unraveling the 
transcriptional regulation of ncx1 during brain ischemia and to identify 
possible tools to increase its transcription. 
 
I.C.8.1. ncx1 Is Transcriptionally Upregulated by NF-kB Under Anoxic 
Conditions 
NF-kB is a family of transcription factors that exists as either a hetero- or 
homodimer of several subunits called RelA (p65), RelB, cRel, p50 and its 
precursor p105 (NF-kB1), and p52 and its precursor p100 (NF-kB2). Some 
dimers are more prevalent than others, and they shuttle between the 
cytoplasm and nucleus, but are predominantly sequestered in the inactive 
state in the cytoplasm by members of the inhibitor of NF-kB (IkB) (Hayden 
and Ghosh, 2008). Upon stimulation by tumor necrosis factor-α (TNF-α), 
oncogenes, or UV light, IkB is firstly phosphorylated by a kinase cascade and 
then degraded by a ubiquitination-mediated proteasomal pathway. As a 
result, NF-kB is released and translocates into the nucleus where it binds 
target DNA sequences and regulates the transcription of several genes 
(Perkins and Gilmore, 2006). Interestingly, a putative NF-kB binding site was 
identified on Br ncx1 promoter at -306\-297 bp from the TSS (Nicholas et al., 
1998). Recently, we demonstrated that under hypoxic conditions, NF-kB 
increases the protein expression of NCX1 in cortical neurons. Moreover, the 
pharmacological blocker SN-50 or the silencing of the NF-kB subunit p65 
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prevents hypoxia-induced NCX1 upregulation (Sirabella et al., 2009). This 
suggests an involvement of the transcriptional factor NF-kB in NCX1 
upregulation in the ischemic brain. 
 
I.C.8.2. ncx1 is a Novel Target Gene for HIF-1 
HIF-1 is a nuclear factor required for transcriptional activation in respons to 
hypoxia. It consists of two subunits: an oxygen-sensitive HIF-1α and a 
constitutively expressed HIF-1β subunit (Wang and Semenza, 1993; Bruick, 
2003). Both contain two motifs named Per-ARNT-Sim (PAS) and basic helix-
loop-helix (bHLH). Whereas both motifs are required for heterodimer 
formation between HIF-1α and HIF-1β subunits, only the bHLH region affords 
specific binding to a region of HIF-1 target genes called hypoxia-responsive 
element (HRE) (Crews, 1998). Under normoxic conditions, HIF-1α protein is 
rapidly hydroxylated by a proline-hydroxylase, and this, in turn, allows the 
recognition by Von Hippel–Lindau tumor suppressor protein that targets HIF-
1α for ubiquitination and proteasomal degradation (Tanimoto et al., 2000) 
(Fig. 7). By contrast, during hypoxia or in the presence of iron chelators and 
divalent cations, such as cobalt, HIF-1α protein scapes proteosomal 
degradation, dimerizes with HIF-1β, generates HIF-1, and translocates into 
the nucleus (Kallio et al., 1997) (Fig. 7). A large variety of genes involved in 
erythropoiesis, iron metabolism (Semenza et al., 1991), angiogenesis (Levy 
et al., 1995), and glucose metabolism (Semenza et al., 1996) are regulated 
by HIF-1. In addition, HIF-1 is upregulated in rat brain during cerebral 
ischemia (Chavez and LaManna, 2002; Matrone et al., 2004), in repetitive 
episodes of hypoxia–reoxygenation (Semenza, 2009), or in ischemic 
preconditioning, a condition in which a period of sublethal ischemia is able to 
protect the brain from a subsequent lethal insult (Pignataro et al., 2009; Taie 
et al., 2009). Thus, in an attempt to unravel the mechanisms involved in the 
regulation of ncx1 expression at the transcriptional level, our collegues 
investigated whether ncx1 gene might be a target of the transcription factor 
HIF-1 in the brain. They reported that: (1) in neuronal cells, NCX1 increased 
expression after oxygen and glucose deprivation or cobalt-induced HIF-1 
activation was prevented by silencing HIF-1; (2) the brain NCX1 promoter 
Introduction – Sodium Calcium Exchanger  
 
- 47 - 
   
contained 2 regions of HIF-1 target genes called hypoxia-responsive 
elements that are sensitive to oxygen and glucose deprivation or cobalt 
chloride; (3) HIF-1 specifically bound hypoxia-responsive elements on brain 
NCX1; (4) HIF-1 silencing prevented NCX1 upregulation and neuroprotection 
induced by ischemic preconditioning; and (5) NCX1 silencing partially 
reverted the preconditioning-induced neuroprotection in rats. NCX1 gene is a 
novel HIF-1 target, and HIF-1 exerts its pro-survival role through NCX1 
upregulation during brain preconditioning (Valsecchi et al., 2011). 
 
 
Figure 7. Regulation and activation pathways of HIF1α (Valsecchi et al., 2013). 
 
I.C.8.3. ncx1 Is Transcriptionally Activated by Akt1 via CREB 
CREB is a member of a large multigene family encompassing at least ten 
different structurally related cAMP-responsive transcription factors (the 
ATF\CREB family). All these bZip class transcription factors form homo- or 
hetero-dimers that could bind, through their leucine zipper domain, to CRE 
elements present on the gene promoters. In particular, the transcriptional 
factor CREB is activated by the phosphorylation of a serine residue, 
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stimulated by a cyclic AMP dependent kinase, Ca2+, growth factors, and 
stress signals (De Cesare et al., 1999). More important, CREB has a distinct 
pro-survival activity and mediates the neuroprotective effect of NGF. Indeed, 
this neurotrophin, upon binding to its trkA receptors, causes the activation of 
the Ser\Thr kinase Akt which ultimately phosphorylates CREB and causes its 
translocation in the nucleus (Autio et al., 2011). Interestingly, Nicholas et al. 
in 1998 reported the presence of a putative CRE binding site in Kd ncx1 
promoter, whereas its existence in the Br ncx1 promoter remained 
unaddressed (Nicholas et al., 1998). Recently, Formisano et al. found 
another CREB binding site on the Br ncx1 promoter, that is responsible for 
the increase in ncx1 expression and activity upon the activation of the 
neuroprotective kinase Akt1. In particular, the activation of the Akt1 by the 
nerve growth factor (NGF) leads to the phosphorylation of CREB and causes 
its translocation into the nucleus that, in turn, binds the CRE sequence at the 
level of the Br ncx1 promoter increasing the transcription of this gene. 
Furthermore, the silencing of CREB prevents the Akt1-induced increase in 
ncx1 protein expression (Formisano et al., 2008). These data demonstrated 
that CREB controls the gene expression of ncx1 and that ncx1 could 
participate to the multiple pro-survival actions of this transcriptional factor. 
 
I.C.8.4. ncx1 is a Novel Target Gene for REST 
The transcriptional repressor REST is a zinc finger protein that binds to a 
conserved 21-bp motif known as RE1 (repressor element 1, also called 
NRSE). Of these base pairs, only 14 are relatively important for its function 
(core REST) (Li et al., 2008). REST perturbation has been described in 
several neurological conditions and in the mechanism of neuropathic pain  
(Ooi and Wood, 2007; Mucha et al., 2010). In brain ischemia, REST is a 
master transcriptional regulator and is associated with selective and delayed 
cell death of hippocampal CA1 neurons. Its main repressive action occur 
through the repression of its two target genes, μ-opioid receptor 1 (Opmr1) 
(Formisano et al., 2007) and AMPA receptor (AMPAR) subunit GluR2 
(Calderone et al., 2003). Recently, it has been evaluated the association of 
ncx1-RE1 sequence with REST and its role in the modulation of NCX1 
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promoter activity by REST. It has been found that: (1) REST binds in a 
sequence specific manner and represses  through H4 deacetylation ncx1 
gene in neuronal cells by recruting CoREST; (2) in neurons and in SH-SY5Y 
cells REST silencing by siRNA and site-direct mutagenesis of REST 
consensus sequence on NCX1 brain promoter determined an increase in 
NCX1 promoter activity; (3) by contrast, REST overexpression caused a 
reduction in NCX1 protein expression and activity; (4) interestingly, in rats 
subjected to transient middle cerebral artery occlusion (tMCAO) and in 
organotypic hippocampal slices or SH-SY5Y cells exposed to oxygen and 
glucose deprivation (OGD) plus reoxygenation (RX), the increase in REST 
was associated with a decrease in NCX1; however, this reduction was 
reverted by REST silencing; (5) REST knocking down, along with the deriving 
NCX1 overexpression in the deep V and VIb cortical layers, caused a marked 
reduction in infarct volume after tMCAO. Notably, double silencing of REST 
and NCX1 completely abolished neuroprotection induced by siREST 
administration. Collectively, these results demonstrate that REST, by 
regulating NCX1 expression, may represent a potential druggable target for 
the treatment of brain ischemia (Formisano et al., 2012) 
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I.D. SP TRANSCRIPTION FACTORS  
I.D.1. The Sp\XKLF Transcription Factor Family 
The Sp\XKLF (Specificity protein\Kruppel-like factor) family of transcription 
factors is united by a particular combination of three conserved Cys2His2zinc 
fingers that form the DNA-binding domain of these factors (Philipsen and 
Suske, 1999). Kruppel-like factors have been named after the Drosophila 
segmentation gene Kruppel that shows a similar arrangement of zinc fingers. 
In human, the Kruppel-like three zinc finger motif was first found in Sp1 
(Kadonaga et al., 1987). Family founder Sp1 is thought to contact DNA with 
the amino acids KHA in the first, RER in the second and RHK in the third zinc 
finger (Fig. 8). As a consequence of the conserved DNA binding motif, 
Sp\XKLF members recognize the same GC-(GGGGCGGGG) and GT-
(GGTGTGGGG) boxes albeit with different affinities due to the substitutions 
of aminoacids in the zinc fingers. GC and GT boxes are important for the 
expression of many different ubiquitous as well as tissue-specific cellular and 
viral genes (Philipsen and Suske, 1999). In addition, these motifs are 
involved in the maintenance of the methylation-free status of the CpG 
islands, as has been shown for the APRT gene. 
 
 
 
Figure 8. The zinc fingers of Sp\XKLF transcription factors. The individual fingers (F1, F2, and F3) 
are depicted as a β-sheet (arrows) and a α-helix (cylinder) held together by a zinc ion (dark grey 
sphere). DNA containing a classical GC box (5’-GGGGCGGGG-3’) is shown as a double array of 
beads on strings with the nucleotide pairs partially overlapping. The aminoacids in the α-helices are 
indicated, and interactions between critical residues (black) in each finger and a specific triplet of 
nucleotides of the GC box are shown with dotted lines (Bouwman et al. 2002). 
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The name of the family indicates that it is subdivided into two major 
subgroups. First, the Sp proteins named after transcription factor Sp1, that 
are not only virtually identical in their zinc finger region but also have similar 
N-terminal motifs (Fig. 9), and second, a more heterogeneous group known 
as KLFs (Philipsen and Suske, 1999). The Sp\XKLF family comprises a large 
number of homologous transcription factors. At present, about 23 members 
of the Sp\XKLF family have been identify: 8 Sp factors and 15 KLF factors. 
Sp1-8 are allocated adjacent to a HOX gene cluster; Sp1 and Sp7 (Osterix) 
are on 12q13.13 (HOX C); Sp2 and Sp6 (KLF14) on 17q21.31\32 (HOXB); 
Sp3 and Sp5 on 2q31.1 (HOX D); Sp4 and Sp8 on 7p21.2 (HOX A). 
Obviously, the regulation of transcription via GC and GT boxes by these 
proteins is a complex process that needs to be tightly controlled. Factors like 
EKLF (Erythroid Kruppel-like Factor), Sp4 and Sp7 show tissue-restricted 
expression patterns and their in vivo requirement in those tissues became 
apparent after gene targeting experiments in mice (Göllner et al., 2001b; 
Nakashima et al., 2002). Others like Sp1 and Sp3 are ubiquitously expressed 
but also fulfil distinct functions, as has been indicated by gene ablation 
studies (Göllner et al., 2001a). 
 
I.D.2. Structural Characteristics of the Sp Factors 
Sp1, the first cloned member of the Sp factors, was identified as a 
transactivator of the SV40 (Simian Virus 40) early promoter (Dynan and 
Tjian, 1983). It was long thought that Sp1 would be essential for the 
transcriptional control of all of the genes that are regulated via GC or GT 
boxes. However, that view changed dramatically when closely related 
transcription factors, now called Sp2, 3 and 4, were cloned. This was 
followed by the identification of Sp5, Sp6 or KLF14, Sp7 or Osterix and Sp8 
(Bouwman et al. 2002). 
Sp5-8 have several small domains in common with Sp1-4 (Fig. 9). Within the 
Sp factors, Sp1, Sp2, Sp3 and Sp4 form a subgroup based on their similar 
modular structure (Fig. 9). Sp1, Sp3 and Sp4 contain two major glutamine-
rich transactivation domains A and B (Fig. 9) that are essential for 
transcriptional activation. Next to these A and B domains, serine\threonine-
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rich sequences are located, that may be a target for post-translational 
modification. While Sp2 has only one glutamine-rich domain, it does share a 
highly charged domain C and a serine\threonine-rich region with the other 
factors. Sp2 has a different consensus-binding site due to the substitution of 
a critical histidine residue by a leucine residue in zinc finger 1 (Kingsley and 
Winoto, 1992). The Sps all contain a so-called Buttonhead box immediately 
N-terminal to the zinc finger domain (Harrison et al., 2000) (Fig. 10A). This 
conserved stretch of 11 amino acid residues may contribute to the 
transactivation potential of the factors, since a deletion of an overlapping 
region results in reduced activity of Sp1 in vitro (Courey and Tjian, 1988). 
Furthermore, domain C, and more specifically the Btd element within domain 
C (Athanikar et al., 1997), is involved in synergistic activation by Sp1 or Sp3 
with sterol-regulatory element-binding proteins (SREBP). Harrison et al. 
(2000) identified another stretch of conserved amino acids consisting of the 
sequence SPLALLAATCSR\KI (Sp box), that is located at the N-terminus of 
the proteins (Fig. 10B). This element contains an endoproteolytic cleavage 
site and is situated close to a region at the N-terminus of Sp1 that targets 
proteasome-dependent degradation in vitro (Su et al., 1999). 
Although not required to direct cleavage, the fact that the Sp box is highly 
conserved indicates that it may have a function in regulation of proteolysis of 
Sp factors. Another possible role for the Sp box may lie in the control of 
transactivation potential via interaction with a putative repressor (Murata et 
al., 1994). Although the functions of the Btd and Sp boxes are not clear at the 
moment, their absence in the XKLF subgroup confirms the relationship 
between the Sp transcription factors. With the exception of the Btd and the 
Sp boxes, the N-terminal regions of Sp5-8 are completely different from 
those of Sp1-4 and more closely related to each other.  
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Figure 9. Structural motifs in Sp factors. Sp and Btd boxes, serine\threonine-rich, glutamine rich and 
highly charged regions, and zinc fingers are indicated, as well as activation (AD) and inhibitory (ID) 
domains. A, B, C, and D modules of Sp1 (Courey and Tjian, 1988) are marked with black bars. Each 
pair of arrow heads points at a PEST domain with a significant PEST-find score (>5.0) (Bouwman et al. 
2002). 
 
 
Figure 10. The Btd and Sp boxes are 
conserved in Sp1-8. (A) Alignment of 
Btd boxes (Wimmer et al., 1993) from 
Drosophila Btd and human Sp factors. 
Strictly and highly (>75%) conserved 
amino acids are indicated with a dark 
grey and a light grey background, 
respectively. (B) Alignment of Sp box-
containing sequences from human Sp 
factors. Strictly and highly (>75%) 
conserved amino acids are indicated 
with a dark grey and a light grey 
background, respectively (Bouwman et 
al. 2002). 
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I.D.3. Functional Analysis of Sp factors: Transactivation Properties 
Traditionally, studies on the transactivation potential of Sp factors have been 
performed in Drosophila SL2 cells, since Sp-like proteins were thought not to 
be present in Drosophila. Although this has been challenged by the cloning of 
the Drosophila Sp1 homologues Buttonhead and D-Sp1, SL2 cell extracts 
are reportedly devoid of Sp-like activities (Courey and Tjian, 1988; Santoro et 
al., 1988). 
 
I.D.3.1. Sp1 
Sp1 can stimulate the transcription from proximal promoters but also from 
distal enhancers (Courey et al., 1989). In vitro experiments suggest that Sp1 
tetramers are involved in the synergistic activation via distant sites. For the 
multimerization, activation domain B appeared to be of critical importance 
(Pascal and Tjian, 1991). Together with domain A, domain B also mediates 
superactivation of Sp1-dependent transcription which can be achieved by 
non-DNA-binding mutants in case of multiple binding sites (Courey et al., 
1989; Hagen et al., 1995). For synergistic activation via binding to multiple 
sites, domain D is required in addition to both transactivation domains 
(Pascal and Tjian, 1991) 
 
I.D.3.2. Sp2 
Since the binding site specificity of Sp2 differs from that of the other Sp 
proteins (Kingsley and Winoto, 1992), the inability of Sp2 to activate 
promoters containing GC boxes can be readily explained. Data from the only 
report of a promoter that is affected by co-transfected Sp2 indicate that this 
transcription factor may function in a cell-type-dependent manner. Sp2 
represses Sp1- and Sp3-driven activation of a construct containing the 
murine CTP: phosphocholine cytidylyl-transferase γ promoterin Drosophila 
cells, but activates the same construct in C3H10T1\2 mammalian cells 
(Bakovic et al., 2000). It is likely that Sp2 has different characteristics than 
Sp1, 3 and 4 since it has only one glutamine rich transactivation domain, 
whereas two domains are required for superactivation and synergistic 
activation by Sp1 (Pascal and Tjian, 1991). 
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I.D.3.3. Sp3 
Although Sp3 was found to be highly homologous to Sp1 with similar 
affinities for GC and GT boxes, it soon became clear that there are some 
striking functional differences. Sp3 can activate transcription from different 
promoters in Drosophila SL2 cells and also in certain mammalian cell lines 
(Galvagni et al., 2001). Upon co-transfection with Sp1, additive and 
synergistic effects were noticed. However, under other circumstances Sp3 is 
at best weakly active, and in the case of promoters containing multiple 
adjacent binding sites Sp3 can repress transcription driven by Sp1 or other 
transcription factors (Birnbaum et al., 1995; Dennig et al., 1996; Majello et al., 
1997). Intriguingly, it should be noted that some promoters could be activated 
by Sp3 in Drosophila cells but not in certain mammalian cells (Hansen et al., 
1999) and viceversa (Sjottem et al.,1996), which further demonstrates the 
complex nature of this transcription factor. 
 
I.D.3.4. Sp4 
As was shown for Sp3, the functional properties of Sp4 turned out to be 
different from those of Sp1, despite obvious structural similarities. Compared 
with Sp1, Sp4 shows similar transactivation potential through its glutamine-
rich activation domains. In addition, Sp4 can be superactivated by fingerless 
Sp1 and repressed by Sp3. However, whereas Sp1 can synergistically 
activate promoters containing multiple binding sites, transactivation by Sp4 
only occurs in an additive manner (Hagen et al., 1995). The transactivation 
potential of Sp4 with respect to different promoters and cell types has not 
been studied as intensively as in the case of Sp1 or Sp3. Several promoters 
could be activated by Sp4 in mammalian cell lines as well as in Drosophila 
cells, but others only appeared to respond to different family members 
(Bouwman et al. 2002). 
 
 
 
 
 
Introduction – Sp Transcription Factors  
 
- 56 - 
   
I.D.4. Specificity in the Regulation of Transcription by Sp Factors 
Sp factors have different functional properties and fulfil specific roles in the 
regulation of biological processes. Unique functions in vivo are demonstrated 
by the clear and different phenotypes of Sp1, Sp3, Sp4 and Sp7 knockout 
mice (Bouwman et al., 2000). On the other hand, under certain 
circumstances apparently depending on cellular conditions and promoter 
context, Sp factors are at least partly redundant. However, various control 
mechanisms could determine the combined effect of these highly 
homologous proteins on transcription regulation. 
 
I.D.4.1. Expression Levels 
The presence of Sp1, Sp3, and perhaps also Sp2, in many if not all different 
cell types, does not imply that the levels of these proteins are not subject to 
specific regulation. Whereas there are no expression data available for Sp2, 
there are several reports on the control of Sp1 and Sp3 expression. 
Expression of Sp1 differs between the cell types during development, and is 
down-regulated in many fully differentiated cells (Saffer et al., 1991). Murine 
Sp1 mRNA can undergo alternative splicing, which during spermatogenesis 
leads to an N-terminally truncated protein that lacks the first glutamine-rich 
transactivation domain and both serine\threonine-rich domains (Persengiev 
et al., 1995). Although the available amount of Sp1 protein is regulated to a 
large extent at the mRNA level, there are also other control mechanisms. 
Sp1 undergoes proteasome-dependent degradation under conditions of 
nutrient starvation and adenylate cyclase stimulation. Initiation of this process 
is thought to be determined by a low glycosylation state of Sp1 and consists 
of an endoproteolytic cleavage triggered by an N-terminal region of Sp1 
(Saffer et al., 1999). The cleavage site is situated in the Sp box that is 
conserved in Sp1-8, which may indicate that proteolysis of other Sp proteins 
is regulated in a similar fashion. Treatment of full-length Sp1 with the serine 
protease myeloblastin, that is downregulated during differentiation, yields a 
fast migrating binding activity similar to that in undifferentiated cells. 
Therefore, myeloblastin or a related protease might provide a switch that 
regulates Sp1-dependent transcription through limited proteolysis. In such a 
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scenario, the small C-terminal peptide could act as a transcription inhibitor, 
since it lacks the transactivation domains but does contain the DNA-binding 
zinc finger region. Apoptosis also coincides with Sp1 proteolysis and the 
action of a caspase-3-like protease in B cells can produce a similarly 
truncated DNA-binding Sp1 isoform (Rickers et al., 1999). The caspase-3 
cleavage site is contained in a region of domain C (Fig. 9) that has earlier 
been identified as a PEST sequence, a putative target motif for inducible 
proteolysis (Mortensen et al., 1997). Although this specific sequence is not 
conserved in the other Sp proteins, they all contain PEST motifs at different 
positions (Fig. 9). Sp1 is also degraded by a cathepsin-like protease termed 
SPase that is expressed in the green monkey kidney cell line CV-1. SPase 
displays some specificity in its action, since it targets Sp1 and the 
phosphorylated retinoblastoma-susceptibility gene product (Rb) but not other 
nuclear factors such as c-Jun or c-Fos. Although not assessed directly, it is 
likely that SPase also degrades Sp3 -and perhaps other Sp\XKLF factors- 
given the complete depletion of different GC box-binding proteins from 
extracts treated with this protease (Nishinaka et al., 1997). Often, for several 
cell types and promoters, Sp1 and Sp3 have been identified as the major 
GC\GT box binding activities. Variation in especially the expression of Sp1 
and Sp3 may have important consequences for transcription activation, given 
the dual nature of Sp3 that can function as an activator as well as an 
inhibitor. There are a number of reports that show variations in the ratio 
Sp1\Sp3 under different cellular conditions. One report suggests that in 
human umbilical vein endothelial cells, hypoxia enhances the amount of Sp1 
protein while Sp3 levels remain unaltered (Xu et al., 2000). Hypoxia induces 
a similar change in the Sp1\Sp3 ratio in myoblasts, albeit in these cells this is 
achieved via the post-transcriptional down-regulation of the Sp3 protein level 
(Discher et al., 1998). In addition, a relatively high Sp1\Sp3 ratio is seen in 
epithelial cells compared to fibroblasts (Apt et al., 1996) and in endothelial 
cells compared to non-endothelial cells (Hata et al., 1998). In most cases, the 
increase of the Sp1\Sp3 ratio has been correlated with the increased 
expression of response genes. In these cellular contexts, those genes might 
be activated by Sp1 and repressed by Sp3, suggesting that transcription is 
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regulated via the co-operative action of both transcription factors. 
Transactivation by Sp3 may also be dependent upon the regulation of 
alternative translation initiation. The nucleotides surrounding the first two 
internal AUG codons allow reasonably efficient translation initiation, giving 
rise to N-terminal truncated Sp3 isoforms (Kennett  et al., 1997). Since these 
truncated Sp3 molecules lack part of the transactivation domains, it is likely 
that they are less potent activators, and repress transcription by competing 
for binding sites. It was then suggested that the contradictory results obtained 
with Sp3 in transactivation assays are a consequence of differences in Sp3 
expression constructs, leading to different ratios of full-length versus 
truncated isoforms (Kennett et al., 1997). This may indeed explain some 
results, but not all, since full-length Sp3 can also repress Sp1-mediated 
transcription (Fandos et al., 1999). 
 
I.D.4.2. Tissue Specificity 
Whereas Sp1, Sp3 and Sp6 are widely expressed, and Sp2 mRNA has been 
detected in various cell lines, Sp4 shows a more restricted expression pattern 
(Scohy et al., 2000). A high level of Sp4 mRNA is predominantly found in 
brain. The robust expression of Sp4 in the central nervous system may 
correlate with the impaired mounting behaviour of Sp4-\- mutant males 
(Nguyên-Trân et al., 2000). Another aspect of the Sp4 knockout phenotype is 
sudden cardiac arrest, and this could be linked to specific expression of Sp4 
in the conductive system of the heart (Nguyên-Trân et al., 2000). Sp5 has a 
highly dynamic expression pattern during mouse embryogenesis in the 
developing brain, the spinal cord, the trigeminal ganglia, the somites and 
additional sites outside the nervous system (Treichel et al., 2001). 
Surprisingly, mice homozygous for a targeted mutation in Sp5 show no overt 
phenotype, but the enhancement of the phenotype of the Brachyury mutation 
(T allele) in compound mutant mice (Sp5 null, T\+) indicates a genetic 
interaction between Sp5 and Brachyury. Sp7 (Osterix) is specifically 
expressed in all developing bones. In Sp7 null mutants no bone formation 
occurs due to a defect in osteoblast differentiation (Nakashima et al., 2002). 
Finally, the expression pattern of Sp8 has not been studied yet. 
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I.D.4.3. Binding Site Specificity 
The binding site specificity of Sp2 is different from all the other Sp\XKLF 
factors. In vitro translated Sp2 binds weakly to a GT box of the T cell antigen 
receptor variable gene segment Vα11.1 promoter, and not at all to an Sp1 
consensus GC box (Kingsley and Winoto, 1992). Based on these data, it is 
likely that Sp2 is involved in regulation of a different set of genes than Sp1, 
Sp3 and Sp4, that all bind to GC and GT boxes with similar affinities (Hagen 
et al., 1992). There are several examples of promoter or enhancer 
sequences that are specifically bound by distinct Sp factors. For instance, 
Sp2 has been shown to bind to a GC box containing region that appears to 
be essential for the activity of the methionine adenosyl-transferase II (MATII) 
promoter in Jurkat cell extracts (Halim et al., 2001). Strikingly, whereas Sp3 
and Sp4 were also part of the complexes bound to this region, Sp1 could not 
be detected. Another example is a GT motif in the neuronal nicotinic 
acetylcholine receptor β4 promoter that specifically interacts with Sp1 and 
Sp3 in extracts from a neuronal cell line and from rat brain (Bigger et al., 
1997). Although Sp2 and Sp4 are present in these cells, there was no 
evidence that they could bind to this motif, while Sp4 antibodies did show 
binding of this factor to a consensus GC box. At present, there is no physical 
or biochemical explanation for this apparent binding site specificity. 
 
I.D.4.4. Post-translational Modifications 
Like many other transcription factors, Sp1 is subject to post-translational 
modifications which can influence its activity. The two major types of post-
translational modifications that are thought to be involved in transcription 
regulation by Sp1 are glycosylation and phosphorylation. 
 
I.D.4.4.1. Glycosylation 
There are no published data that show glycosylation of Sp proteins other 
than Sp1, although they do contain putative glycosylation sites (Hagen et al., 
1992). O-glycosylation has been related to the nuclear localization, the 
stability and\or the transactivation potential of Sp1. However, direct evidence 
for the effect of glycosylation on Sp1 function has not been obtained, and 
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with respect to transactivation potential, it has recently been shown that 
glycosylation can also have adverse effects (Yang et al., 2001). One of the 
suggested explanations for increased transactivation was that GlcNAc 
residues might act as ligands for recognition by components of the 
transcription machinery (Jackson and Tjian, 1988). In contrast, the opposite 
has been observed for the glycosylation of the carboxy-terminal part of Sp1 
activation domain B. Interactions between this domain and dTAF(II)110 and 
full-length Sp1 are markedly decreased upon glycosylation, correlating with a 
decreased transactivation potential in vitro (Roos et al., 1997) and in vivo 
(Yang et al., 2001). Glucose deprivation in combination with adenylate 
cyclase stimulation results in reduced glycosylation of Sp1, associated with 
an increased susceptibility to proteasome-dependent degradation. The 
process is blocked in cells treated with glucosamine, a metabolic derivative of 
glucose that is used primarily asa substrate for protein glycosylation (Han 
and Kudlow, 1997). It has therefore been suggested that glycosylation blocks 
protein interactions and prevents Sp1 from entering into protein complexes 
that are readily degraded by proteasomes (Roos et al.,1997). 
 
I.D.4.4.2. Phosphorylation 
O-glycosylated proteins are also phospho-proteins. Sp1 becomes 
phosphorylated at its N-terminus by DNA-dependent protein kinase upon 
binding to DNA (Gottlieb and Jackson, 1993). The C-terminus of Sp1 can 
also be phosphorylated; this has been linked to cell cycle progression from 
G0 to G1. In vitro data suggest that the unknown kinase that mediates this 
phosphorylation specifically targets serine residues in the most N-terminal 
zinc fingers 1 and 2 (Black et al., 1999). Several additional reports link Sp1 
phosphorylation with decreased binding activity (Zhu and Liao, 2000), but 
phosphorylation can also result in increased binding (Haidweger et al., 2001). 
In some cases, increased binding through phosphorylation has been 
correlated with enhanced transactivation. For instance, phosphorylation of 
Sp1 by protein kinase C-γ (PKC-γ) in smooth muscle cells stimulates platelet-
derived growth factor β-chain (PDGF-β) expression. Interestingly, PKC-γ, 
that can directly interact with the Sp1 zinc finger region, has no apparent 
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effect on Sp3 (Rafty and Khachigian, 2001). Apparently, certain kinases can 
specifically regulate the transcriptional activity of distinct Sp proteins. 
Nevertheless, it is likely that there are also forms of phosphorylation that 
have a similar effect on different Sp factors. Sp1 interacts with cyclin A and 
can be phosphorylated via a cyclin A-associated kinase. As a result, DNA 
binding is increased, concomitantly with transactivation mediated via Sp1-
binding sites. Since Sp3 DNA binding is similarly affected, and Sp3 as well as 
Sp4 have been reported to interact with cyclin A, this suggests a common 
regulatory pathway (Haidweger et al., 2001). 
 
I.D.4.4.3. Acetylation of the Inhibitory Domain of Sp3 
Transactivation assays with mutant proteins revealed that the transactivation 
potential of Sp3 is influenced by an inhibitory domain (Dennig et al., 1996). 
This domain resides in a highly charged stretch of amino acids that is not 
present in the comparable region of Sp1 (domain C; Fig.9). The presence of 
a repressive module explains the earlier inactivity of the N-terminal region of 
Sp3, despite the presence of glutamine-rich domains that resemble the Sp1 
transactivation domains A and B (Hagen et al., 1994). Mutation of a critical 
KEE amino acid triplet results in relief of repression and potentates Sp3 
transactivation, especially of promoters containing multiple binding sites 
(Dennig et al., 1996). Recent data show that the lysine residue in this KEE 
triplet is highly acetylated in vivo. A mutant of Sp3 lacking this lysine revealed 
that it is responsible for the low transcriptional activity of Sp3 in vivo. Since 
this Sp3 mutant is no longer highly acetylated in vivo, these results indicate 
that the transcriptional activity of Sp3 is regulated by acetylation (Braun et al., 
2001). 
 
I.D.5. Physiological Function of Sp-Proteins 
In the past, a large variety of biological functions have been assigned to Sp1-
binding sites and to Sp1. However, the identification of the three paralogous 
proteins Sp2, Sp3 and Sp4 raises the question as to which tasks are 
performed by which protein. This question is particularly interesting for Sp1 
and Sp3 because both proteins are present in the same cell and are 
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indistinguishable in their DNA-binding specificity. Gene disruption in mice is a 
powerful tool for obtaining information on specific functions of individual Sp-
proteins. Given that Sp1 is implicated in the activation of a very large number 
of genes, such as housekeeping, tissue-specific and cell cycle-regulated 
genes, and is required to prevent methylation of CpG islands (Macleod et al., 
1994; Brandeis et al., 1994), one would expect that cells lacking Sp1 would 
not survive. Surprisingly, this is not the case. S. Philipsen and his coworkers 
found that Sp1-deficient embryonic stem cells (ES cells) are viable, have 
normal growth characteristics and can be induced to differentiate and form 
embryoid bodies as efficiently as wild type ES cells (Marin et al., 1997). 
Nevertheless, Sp1 is essential for normal mouse embryogenesis. The Sp1-
knockout embryos are severely retarded in development and they all died 
around day 11 of gestation. They displayed a marked heterogeneity in 
phenotype indicating that Sp1 has indeed a general function in many cell 
types. Interestingly, the defects in Sp1-\-mice are caused by a cell 
autonomous mechanism. Sp1-\- ES cells injected into blastocysts contributed 
efficiently to chimaeric embryos at early stages but after day E 11 they 
rapidly declined with no contribution to newborn mice. Thus, Sp1 appears to 
be a transcription factor whose function is essential for differentiated cells 
after day 10 of development. Independently of the severe developmental 
defects of the Sp1 null mice, the embryos express many putative Sp1 target 
genes at normal levels, including housekeeping and cell-cycle regulated 
genes. In addition, CpG-islands remained methylation free. So far, the only 
genes which were found to be expressed at a lower level in Sp1-\-mice are 
the thymidine kinase and the methyl-CpG binding protein 2 (MeCP2) genes 
(Marin et al., 1997). The Sp1-knockout demonstrated that Sp1 is not 
essential for the expression of many genes previously shown be activated in 
cell culture transfection experiments. One could speculate that other Sp-
family members compensate at early embryonic stages, at least in part for 
the loss of Sp1 activity. Sp3 would be a good candidate because it is also 
ubiquitously expressed, has the potential to activate transcription and its 
DNA-binding activity is indistinguishable from Sp1. In that regard, the 
phenotype of Sp3 knockout mice will be of great interest. Sp4, the tissue 
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restricted member of the Sp-family, is predominantly expressed in the brain 
but also detectable in epithelial tissues, testis and developing teeth (Hagen et 
al., 1992). Disruption of the mouse Sp4 gene revealed that it is important for 
early post-natal survival (Supp et al., 1996). Approximately two thirds of the 
Sp4-\- mice die within a few days of birth. The cause of the early death 
remains unknown. Those mice which survive are significantly smaller than 
their wild type littermates. The reduced body weight appears to result from an 
unknown, but growth hormone independent, mechanism (Supp et al., 1996). 
Interestingly, surviving mice exhibit a striking sex-specific abnormality. While 
fertility of the female mutants appears normal, males do not breed although 
their reproductive organs are fully developed and apparently normal. It 
appears that male Sp4-\- mice are unable to copulate. The most likely cause 
of this abnormal behavior is a neurological defect. The hypothalamus and the 
vomeronasal organ are known to play important roles in reproductive 
physiology and behavior. However, both structures are histologically normal 
in Sp4-\- mice. Thus, we await further investigation to understand the role of 
Sp4 and to identify its target genes. In that context, it should be noted that for 
both the Sp1 and the Sp4 knockouts, the zinc finger regions have been 
chosen to inactivate the genes. In both cases the N-terminal part encoding 
the transactivation domains are still expressed (Marin et al., 1997; Supp et 
al., 1996). One could speculate that the activation domains on their own 
might act as a gain-of-function or might interfere with other Sp-family 
members. In the case of the Sp4 knockout such a scenario does not seem to 
be the case. Knockout Sp4-\- mice which do not express the N-terminal part 
of the protein manifest the same phenotype (Suske et al. 1999). 
 
I.D.6. Sp1 and Sp3 Are Oxidative Stress-Inducible, Antideath 
Transcription Factors in Brain 
Sp1 activities have been shown to change in response to apoptosis inducing 
stimuli. Indeed, polyglutamine expansions in the huntingtin protein can 
induce neuronal toxicity, in part, by sequestering Sp1 and one of its 
coactivators, TATA binding protein-associated factor (TAF)II130, suggesting 
a role for Sp1 in neuronal survival (Dunah et al., 2002). Notably, Sp1 has 
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been shown to regulate prosurvival proteins [e.g., the inhibitor of apoptosis 
(IAP) protein, survivin, and manganese superoxide dismutase], as well as 
prodeath proteins [e.g., Fas ligand and 12-lipoxygenase (Ryu et al., 2003a). 
Like other transcription factors, the role of Sp1 in regulating cell death may 
depend on a number of factors, such as the cell type and the death stimulus 
(Lin et al., 1998). Ryu et colleagues (2003) demonstrated that oxidative 
stress significantly induces Sp1 and Sp3 protein levels and DNA binding in 
neurons in vitro and in vivo. Moreover, they found that the enforced 
expression of Sp1 or Sp3 is neuroprotective. These findings established Sp1 
and Sp3 as redox-regulated transcriptional activators that enhance survival in 
cortical neurons. Sp1 and Sp3 are therefore sufficient components of the 
protective, homeostatic response to oxidative stress and one potential 
consequence of oxidative stress, DNA damage, in neurons (Ryu et al., 
2003b).  
Indeed, recent studies suggest that Sp1 motifs are responsible for the 
regulation of the IAP protein survivin (Li and Altieri, 1999). Members of the 
IAP protein family have been shown to suppress apoptosis induced by 
oxidative stress by directly suppressing the activity of terminal caspase-3 and 
caspase-7 (Tamm et al., 1998; Suzuki et al., 2000). Interestingly, survivin is 
expressed not only in common human cancers, but also in some types of 
embryonic neurons (Adida et al., 1998), suggesting that this protein is poised 
to act as an inhibitor of apoptosis in the cortical neurons. Bcl-2 and Bcl-xL, 
two other general inhibitors of apoptosis, also have essential Sp1 sites in 
their promoters (Grillot et al., 1997; Dong et al., 1999), and p53 has been 
shown to repress the expression of the antiapoptotic factor telomerase by 
binding to cognate Sp1 motifs in the telomerase promoter (Kanaya et al., 
2000). Taken together, these observations support an antiapoptotic role for 
Sp1.  
The data are consistent with a model in which Sp1 is a part of a 
compensatory genetic program to oxidative stress in neurons. A prediction of 
this model is that neurons with acquired or inherited defects in Sp1 signaling 
will be more vulnerable to oxidants. Indeed, autopsy tissue from HD patients 
shows prominent defects in Sp1 DNA binding despite increased Sp1 
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levelsand increased markers of oxidative damage (Browne et al., 1999). 
Furthermore, toxicity of cultured neurons induced by the forced expression of 
mutant huntingtin with pathological numbers of polyglutamine repeats can be 
abrogated by the coexpression of Sp1 and its coactivator TAFII130 (Dunah et 
al., 2002; Li et al., 2002) or by the exogenous addition of small-molecule 
antioxidants (Wyttenbach et al., 2002).  
Recently it has been found that enhanced neuronal protection by histone 
deacetylase inhibitors in response to oxidative stress is mediated by Sp1 
acetylation in primary neurons and in an animal model of Huntington’s 
disease. The fact that acute oxidative stress induces Sp1 acetylation 
represents the protective role of Sp1 as the frustrated attempt of neurons to 
protect themselves from oxidative stress-induced cell death. These studies 
strongly imply that Sp1 promotes neuronal survival in response to oxidative 
stress (Lee et al., 2006). 
Nevertheless, these findings suggest that small-molecule activators of Sp1-
dependent gene expression may be propitious therapeutic targets for a host 
of neurodegenerative conditions, including HD, Parkinson’s disease, 
amyotrophic lateral sclerosis, and stroke, which in some cases have been 
associated with expanded polyglutamine repeats and in all cases have been 
associated with oxidative stress. (Ryu et al., 2003a). 
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II. AIM OF THE STUDY 
Changes in Na+-Ca2+ exchanger 1 (ncx1) gene expression, an ubiquitous 
plasma membrane protein regulating cellular calcium and sodium 
homeostasis in the brain is important to the progression of cerebral ischemia 
(Annunziato et al., 2004). Indeed, studies have shown that ncx1 knocking 
down, caused a marked increase in infarct volume after brain ischemia 
(Pignataro et al., 2004; Boscia et al., 2006), and partially reverted the 
preconditioning-induced neuroprotection (Pignataro et al., 2011a). It is known 
that NCX1 reduction in brain ischemia is due to the transcriptional repressor 
REST (Formisano et al., 2012), that regulates global gene expression after 
stroke (Noh et al., 2012; Schweizer et al., 2013), while NCX1 increase in 
ischemic preconditioning (PC), is determined by the transcriptional activator 
HIF-1 (Valsecchi et al., 2011). Interestingly, ncx1 brain promoter (ncx1-Br) 
sequence contains several consensus binding sites for Specificity protein 1 
(Sp1). Sp transcription factors is a family comprising of four isoforms Sp1, 2, 
3 and 4 (Suske, 1999), that bind to the same Sp1 recognition sequence with 
similar affinities (Hwang et al., 2001), except Sp2 that does not bind to the 
classical Sp1 sequence, but to a GT-rich element (Philipsen and Suske, 
1999). Interestingly, Sp1 and Sp3 can both act as activators 
(Ammanamanchi et al., 2003; Ravache et al., 2010) or repressors 
(Ammanamanchi and Brattain, 2001; Law et al., 2011) of gene expression, 
Sp4 generally acts as transcription activator (Ishimaru et al., 2007). It has 
been recently reported that Sp1 is involved in NGF-induced regulation of 
ncx1 (Sirabella et al., 2012). On the basis of these results, a first aim of this 
study was to evaluate the association of Sp1 sequences with Sp transcription 
factor family and its role in the modulation of NCX1 expression during brain 
ischemia and ischemic preconditioning. We found in cortical neurons that 
Sp1 acts as activator while Sp3 acts as repressor of ncx1 expression. 
Furthermore, considering that REST reduces NCX1 expression during 
cerebral ischemia (Formisano et al., 2012) and that HIF-1 increases NCX1 
expression during ischemic preconditioning plus ischemia, in the present 
study we investigated the possible interaction of REST with Sp3 and HIF-1 
with Sp1 in brain ischemia and ischemic preconditioning plus ischemia, 
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respectively. In addition, since it has been reported that both REST and Sp3 
can modulate their target genes via the histone deacetylases family (HDAC) 
(Won et al., 2002; Rodenas-Ruano et al., 2012) and that histone acetyl 
transferase (HAT) is involved in HIF-1 and Sp1 induced gene expression 
(Billon et al., 1999; Ke and Costa, 2006), we investigated: (1) the interaction 
between REST and Sp3 to form a protein complex which in turn recruit 
HDAC1 and HDAC2 repressing ncx1expression in an in vivo model of brain 
ischemia, and (2) the interaction between HIF-1 and Sp1 to form a protein 
complex which recruit the HAT p300 to activate ncx1 expression in an in vivo 
model of brain ischemic preconditioning. Finally, we assessed the effect of 
the HDAC class I inhibitor MS-275 (Lanzillotta et al., 2012) and histone 
acetyltransferase (HAT) p300 inhibitor C646 (Min et al., 2010) on cell survival 
and its correlation with NCX1 expression in cortical neurons subjected to 
OGD plus Reoxygenation (OGD\Rx), and to IPC plus OGD\Rx. 
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III. MATERIALS AND METHODS 
III.1. Materials 
All restriction enzymes and DNA modifying enzymes were purchased from 
New England Biolabs (Ipswich, MA) or Promega (Milan, IT). Luciferase 
reporter kits and luciferase vectors were from Promega (Milan, IT). Synthetic 
oligonucleotides were from Primm (Milan, IT). siRNAs against rat REST and 
HIF-1 were already published (Valsecchi et al., 2011; Formisano et al., 
2012), whereas siRNAs for Sp1 (siSp1) (SI02039044), Sp3 (siSp3) 
(SI05434387), Sp4 (siSp4) (SI02039114), p300 (sip300) (SI02989693) and 
negative control siCONTROL (siCTL) (1027280) were from Qiagen (Milan, 
IT). To knock-down rat HDAC1 and HDAC2 MISSION siRNAs from Sigma 
(Milan, IT) were used. The sequences of siRNAs used are as follows: for 
HDAC1 Forward, 5′-CUUUGAAUACUUUGGACCA(dT) (dT)-3′ and Reverse, 
5′-UGGUCCAAAGUAUUCAAAG(dT)(dT)-3′; for HDAC2 Forward, 5′-
GAUAUCGGGGAAUUAUUAUU(dT) (dT)-3′ and  Reverse, 5′-
AAUAAUAAUUCCCGAUAUC(dT) (dT)-3′. Two sets of siRNAs were tested 
for Sp1, Sp3, Sp4, p300, HDAC1 and HDAC2 and the set that was more 
effective was chosen for the experimentation. The construct to silence NCX1 
(siNCX1) and mismatch sequence cloned in the same vector (MS siNCX1) 
were used as previously described (Formisano et al., 2008; Sirabella et al., 
2009). The constructs pN3 and pN3-Sp1,3,4, carrying Sp1,3,4 cDNAs, were 
kindly provided by Prof. G. Suske (Marburg, Germany). The constructs 
pKCRH-NCX1 overexpressing NCX1 (NCX1) and the empty vector (pKCRH) 
were kindly provided by Prof. Iwamoto (Fukuoka, Japan) (Iwamoto et al., 
2004a). The HDAC inhibitor MS-275 (EPS002) and HAT-inhibitor C646 
(SML002) were obtained from Sigma (Milan, IT). Both were dissolved in 
dimethyl sulfoxide (DMSO) and diluted before application to a final DMSO 
concentration lower than 0.2%. All common reagents were of the highest 
quality and were purchased from Sigma (Milan, IT).  
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III.2. Primary Cortical Neurons 
Primary cortical neurons were prepared from 17-day-old Wistar rat embryos 
(Charles River, Calco, IT) and used after 7 days. Cytosine arabinoside (2.5 
μM) was added the second day to reduce glial contamination. The 
experiments on primary cortical neurons were performed according the 
procedures described in experimental protocols approved by Ethical 
Committee of the “Federico II” University of Naples. Briefly, dissection and 
dissociation were performed in Ca2+\Mg2+-free phosphate-buffered saline 
(PBS) containing glucose (30 mM\l). Tissues were incubated with papain for 
10 minutes at 37°C and dissociated by trituration in Earl’s Balanced Salt 
Solution (EBSS) containing DNAse (0,16 U\ml), bovine serum albumin (10 
mg\ml), and ovomucoid (10 mg\ml). Neurons, were plated in plastic Petri 
dishes (Falcon™ Becton-Dickinson, Buccinasco, IT) pre-coated with poly-D-
lysine (20 µg\ml), were grown in MEM\F12 containing glucose, 5% of 
deactivated fetal bovine serum (FBS) and 5% of horse serum (HS), 
glutamine (2 mM\l), penicillin (50 Units\ml), and streptomycin (50 μg\ml) 
(Invitrogen, Milan, IT). Cell density was 1x106 cells\well for 24-well plate for 
LDH assay, 2x106 cells\well for 12-well plate for luciferase assay, 5x106 
cells\well for 60 mm for qRT-PCR and 15x106 cells\well for 100 mm for 
Western Blot analysis and ChIP analysis. 
 
III.3. Transfection with Expression Plasmids or Small Interfering RNA 
(siRNA) and Luciferase Reporter Assay, in Cortical Neurons  
Cortical neurons were transfected with 50nM of siCTL, siSp1, siSp3 or siSp4. 
To overexpress pN3, Sp1, Sp3, Sp4, pKCRH, pKCRH-NCX1 and to silence 
NCX1 with siNCX1 and MS siNCX1, neurons were transfected with above 
mentioned constructs in the following amounts: 0.5 μg for 24-well plates, 1.3 
μg for 12-well plates, 7 μg for 60 mm plates and 15 μg for 100 mm plates. 
Each transfection was performed at 7 DIV in Optimem with Lipofectamine 
LTX (15338-100, Invitrogen, Milan, IT), as suggested by the producer. After 2 
hours it was replaced with fresh medium. For luciferase assay experiments, 
cortical neurons at 7 DIV were transfected in 12-well plates. Cells were co-
transfected with 2 μg of total DNA vectors; the reporters (560 ng each) were 
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the following: (1) the pGL3 construct, (2) the pGL3-ncx1 (short ncx1 
promoter), (3) the pGL3-ncx1\Sp1Bmut (GGCGGCGGGC), (4) the pGL3-
ncx1\Sp1Cmut (CGGGCGGGG), (5) the pGL3-ncx1\Sp1Dmut 
(GGGAGGGG), (6) the pGL3-ncx1\Sp1Emut (GGCCCCGGC), (7) the pGL3-
ncx1\Sp1CDEmut (that contain Sp1 sites C,D and E simultaneously 
mutated), in which underlined bases represent mutated sequences in pGL3. 
Mutagenesis of the Sp1 sites in the promoter was performed using the 
QuickChange site-directed mutagenesis kit from Stratagene. To overexpress 
Sp1, Sp3 and Sp4 we used the expression vectors and the empty vector pN3 
(1.3 μg each). For RNA interference, 50nM of specific siCTL, siSp1, siSp3 or 
siSp4 were used. Each transfection mix also contained 140 ng of the pRL-TK 
control vector expressing renilla luciferase gene. After a 2h incubation period, 
the medium was replaced with a fresh one and analyzed after 24h with Dual-
Luciferase Reporter Assay System kit (E1910) (Promega, Milan, IT), as 
already reported (Formisano et al., 2012). 
 
III.4. Combined Oxygen and Glucose Deprivation (OGD) and 
Reoxygenation (Rx) 
OGD in neurons was performed in a medium previously saturated with 95% 
N2 and 5% CO2 for 20 min and containing: NaCl 116 mmol\L, KCl 5.4 
mmol\L, MgSO4 0.8 mmol\L, NaHCO3 26.2 mmol\L, NaH2PO4 1 mmol\L, 
CaCl2 1.8 mmol\L, glycine 0.01 mmol\L, and 0.001 w\v phenol red, and then 
placed in a hypoxia chamber for 3 hours (Billups Rothemberg Inc. Del Mar., 
CA, USA) (temperature 37°C, atmosphere 5% CO2 and 95% N2). To 
terminate OGD, cells were removed from the hypoxic chamber, and then 
changed with normal medium for 24 hours of Reoxygenation (Rx). For 
preconditioning (PC), the cortical neurons were exposed to 30 min of OGD, 
as described above, and then placed in normal medium. 24 hours after the 
PC stimulus, the cultures were again subjected to OGD for 3 hours followed 
by 24 hours of Rx. Transfections with pKCRH-NCX1, pKCRH, siNCX1 and 
MS siNCX1 were performed at 7 DIV; after 24 hours cells were subjected to 
OGD\Rx or IPC+OGD\Rx. MS-275 1 μM was added at the end of OGD 
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period for 2 hours whereas C646 20 μM was added to the medium 30 min 
before PC, and throughout the IPC phase.  
 
III.5. Quantitative Real-Time PCR (qRT-PCR) Analysis 
The first-strand cDNA and quantitative real-time PCR was carried out as 
previously described (Formisano et al., 2007; Formisano et al., 2012). Using 
1\10 of the cDNAs as a template, the quantitative real-time PCR was carried 
out in a 7500 fast real-time PCR system (Applied Biosystems, Monza, IT) by 
Fast SYBR Green Master Mix (cod. 4385610; Applied Biosystems, Monza, 
IT). Samples were amplified simultaneously in triplicate in one assay as 
follows: heating 2 min @ 50º C, denaturation 10 min @ 95º C, amplification 
and quantification 35 cycles of 15 sec @ 95º C; 1 min @ 60º C with a single 
fluorescence measurement. PCR data was collected using ABI Prism 7000 
SDS software (Applied Biosystems). After PCR, products were 
electrophoretically separated on 1,5% agarose gels and bands were 
visualized with ethidium bromide and documented using a Gel Doc Imaging 
System (Bio-Rad, Hercules, CA). Normalization of the data was performed by 
HPRT as an internal control. Differences in mRNA content between groups 
were calculated as normalized values by using 2-ΔΔct formula and results 
were tested for significance using Relative Expression Software Tool (REST 
©) (Formisano et al., 2007). The oligonucleotide sequences for NCX1, NCX3 
and Hypoxanthine phosphoribosyltransferase (HPRT) were already 
published (Pignataro et al., 2011b; Formisano et al., 2012). 
 
III.6. Western Blotting 
For Western blot analysis, cells (or tissues) were collected in ice-cold lysis 
buffer (Formisano et al., 2012) containing anti-protease cocktail (P8340 
Sigma, Milan, IT). For HDAC1, HDAC2 and Acetyl-histone H3 expression, 
proteins (50 µg) were separated on 12% SDS polyacrylamide gels, whereas 
for NCX1, Sp1, Sp3, Sp4, REST, HIF-1 and p300 expression, proteins (100 
µg) were separated on 8% SDS-polyacrylamide gels. Both were transferred 
onto Hybond ECL nitrocellulose membranes (Amersham, Milan, IT). 
Membranes were blocked with 5% non fat dry milk in 0.1% Tween 20 
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(Sigma, Milan, IT) (2 mM Tris-HCl and 50 mM NaCl pH 7.5) for 2 hours at 
room temperature, and then they were incubated overnight at 4°C in the 
blocking buffer with the 1:1000 monoclonal antibodies against HDAC1 (5356) 
and HDAC2 (5113) (Cell-Signaling, EuroClone, Milan, IT), p300 (sc-48343) 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), HIF-1(MAB5382) 
(Millipore, Milan, IT) and 1:2000 β-actin (A 4700) (Sigma, Milan, IT), either 
with the 1:1000 polyclonal antibodies against REST (07-579) and Acetyl-
histone H3 (06-866) (Millipore, Milan, IT), NCX1 (p 11-13) (Swant, 
Bellinzona, Switzerland), Sp1 (sc-14027), Sp3 (sc-644) and Sp4 (sc-645) 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). Finally, after the 
incubation with primary antibodies, membranes were washed with 0.1% 
Tween 20, followed by incubation with secondary antibodies for 1 h at room 
temperature. Immunoreactive bands were detected with the ECL reagent 
(Amersham). The optical density of the bands, normalized to β-actin, was 
determined by Chemi-Doc Imaging System (Bio-Rad, Hercules, CA). 
 
III.7. Chromatin Immunoprecipitation (ChIP) and re-ChiP Assay 
Brain tissue and cortical neurons were processed into chromatin by use of 
published protocols (Formisano et al., 2007; Formisano et al., 2012) with 
some modifications. Cells and tissues were cross-linked with 1% 
formaldehyde, and then reaction was stopped by adding glycine to a final 
concentration of 0.125 M. Brain tissue and cells were washed three times in 
cold PBS containing proteinase inhibitors and then collected in a buffer 
containing: 50mM Tris pH 8.1, 1% SDS, 10 mM EDTA, and anti-protease 
cocktail. For cell and tissue samples, chromatin was fragmented by 
sonication into 200–500 bp fragments (6 rounds for cells and 15 rounds for 
brain tissue of 15 1-s pulses at 50% of maximum potency) by a Bandelin 
Sonopuls HD 2070 ultrasonic homogenizer (Bandelin, Berlin, Germany). 
Equal amounts of chromatin lysates (50 μg for cells and 70 μg for tissues) 
were incubated overnight with 5μg of antibody for Sp1 (sc-14027), Sp3 (sc-
644), Sp4 (sc-645), p300 (sc-48343) (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA), REST (07-579), acetyl-Histone H4 (06-866), Hypoxia Inducible 
Factor 1 α (MAB5382) (Millipore, Milan, IT), HDAC1 (5356), HDAC2 (5113) 
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(Cell-Signaling, EuroClone, Milan, IT), RNA POL II (R1530) (Sigma, Milan, 
IT) and normal rabbit or mouse IgG were used as negative controls. After 
immunoprecipitation, the DNA-histone complex was collected with 40 μl of 
salmon sperm DNA\protein A or G -agarose beads for 2 hours (16-157, 16-
201) (Millipore, Milan, IT). After rotating for 2 hours at 4°C on a spinning 
wheel, the beads were washed once with each of the following buffers in the 
order shown: high-salt buffer (0.1% SDS, 1% Triton, 2mM EDTA, 20mM Tris 
HCl pH 8.1, 500 mM NaCl); low-salt buffer (0.1% SDS, 1% Triton, 2mM 
EDTA, 20mM Tris HCl pH 8.1, 150mM NaCl); LiCl buffer (0.25M LiCl, 1% 
NP40, 1% deoxycholate, 1mM EDTA, 10mM Tris HCl pH 8.1), and two times 
at room temperature with TE buffer (10mM Tris pH 8.1 and 1mM EDTA). The 
precipitated fragments were eluted with a buffer containing 1% SDS and 
0.1M NaHCO3. DNA was analyzed by qRT-PCR using Fast SYBR Green 
Master Mix (cod 4385610; Applied Biosystems, Milan, IT). Heating 2 min @ 
50ºC, denaturation 10 min @ 95ºC, amplification and quantification 35 cycles 
of 30 sec @ 95ºC; 1 min @ 60°C with a single fluorescence measurement. 
The binding activity was graphically represented as the percentage of total 
input of chromatin and the results were analyzed using a previously 
described formula (Renthal et al., 2007). The following oligonucleotides were 
used for the amplification of immunoprecipitated DNA: ncx1-Br (A) Forward 
5’-CCGCTGGGGAAACCCCTGCC-3’ and Reverse 5’-
GCGCTGCAACTTTTCTTTTGAACG-3’, ncx1-Br (B) Forward 5’-
GGGTGCAGAAGAGAGCGCTGGC-3’ and  Reverse 5’- 
GCACAAAGCGCGGCGGCCCG-3’. For each amplification, melting curves 
and gel electrophoresis of the PCR product were used to verify their 
identities. Samples were amplified simultaneously in triplicate in one assay 
run. Re-ChIP experiments were employed to detect the simultaneous 
presence of Sp3 and Sp1 with REST or HIF-1, respectively. Beads from the 
first ChIP with anti-Sp1 and anti-Sp3 were incubated with an equal volume of 
10 nM dithiothreitol at 37 °C for 30 min, centrifuged at 12000 rpm for 1 min to 
elute DNA-bound proteins. The elution was repeated twice. The final elute 
was diluted 1:10 in lysis buffer containing a protease inhibitor cocktail and re-
immunoprecipitated with the anti-REST, the anti-HIF-1 antibodies, or IgG. 
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ChIP and input DNA were analyzed by PCR. Denaturation 10 min @ 95ºC, 
35 cycles of 30 sec @ 95ºC; 1 min @ 60ºC; 1 min @ 72ºC. The PCR 
products were electrophoresed on a 1.5% agarose gel and stained with 
ethidium bromide. For ChIP and Re-ChIP experiments we used ncx1-Br (B) 
primers, since the amplified sequence of ncx1-Br contains the binding sites 
for REST (-18\+1) (Formisano et al., 2012), HIF-1 (-331\-327 and -164\-160) 
(Valsecchi et al., 2011), Sp1 and Sp3. 
 
III.8. Quantitation of neuronal injury 
Neuronal injury was assessed by measurement of LDH efflux into the 
medium after OGD\Rx or IPC+OGD\Rx. In neuronal cultures, LDH activity in 
the medium is correlated with the number of damaged cells (Koh and Choi, 
1987). Cytosolic levels of LDH in the extracellular medium were measured by 
using an LDH Cytotoxicity Kit (1000882 Cayman, DBA, Milan, IT). Briefly, 
after induction of OGD\RX or PC+OGD\Rx, the medium was removed and 
sampled for LDH content by measuring the absorbance at 490 nm using a 
spectrophotometer BioPhotometer (Eppendorf, Hamburg, Germany). The 
results were expressed as a percentage of LDH release versus a control 
obtained in untreated sister cultures. 
 
III.9. In vivo studies 
 
III.9.1. Experimental groups 
Male Sprague-Dawley rats (Charles River) weighing 250 to 300 g were 
housed under diurnal lighting conditions (12 h darkness\light). Experiments 
were performed according to the international guidelines for animal research. 
All experiments were approved by the Institutional Animal Care and Use 
Committee of the “Federico II” University of Naples, IT. 
 
III.9.2. Transient Focal Ischemia and Ischemic Preconditioning 
Transient focal ischemia was induced as previously described (Valsecchi et 
al., 2011), by suture occlusion of the middle cerebral artery (MCA) in male 
rats anesthetized using 1.5% sevoflurane, 70% N2O, and 28.5% O2. 
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Achievement of ischemia was confirmed by monitoring regional cerebral 
blood flow through laser Doppler (PF5001; Perimed). Animals not showing a 
cerebral blood flow reduction of at least 70% were excluded from the study. 
Animals that did not show a cerebral blood flow reduction of at least 70% 
were excluded from the experimental group, as well as animals that died 
after ischemia induction. Rats were divided into 4 experimental groups: (1) 
sham-operated (CTL); (2) preconditioned rats (PC); (3) ischemic, subjected 
to transient MCA occlusion (tMCAO); and (4) preconditioned ischemic rats 
(PC+tMCAO). The sham-operated animals underwent the same 
experimental conditions except that the filament was not introduced; in the 
ischemic group, the MCA was occluded for 100 minutes; in the 
preconditioned ischemic group, rats were subjected to 30 minutes of tMCAO 
72 hours before 100 minutes of tMCAO. The siRNAs, used in ischemic and 
preconditioned ischemic  rats were intracerebroventricularly (icv) 
administered (1 μl) as previously reported at the concentrations of 20 μM for 
REST (Formisano et al., 2012), 3 μM for HIF-1 (Valsecchi et al., 2011) and 
10 μM for Sp1, Sp3, HDAC1, HDAC2 and p300. For tMCAO and PC+tMCAO 
experiments, icv injections were performed three times, i.e., 18 h and 6 h 
before and 24 h after ischemia induction and 24, 18, and 6 hours before 
ischemic preconditioning induction. All animals were euthanized 24 h after 
the 100 min tMCAO. Rectal temperature was maintained at 37±0.5°C with a 
thermostatically controlled heating pad and a catheter was inserted into the 
femoral artery to measure arterial blood gases before and after ischemia 
(Rapid Laboratory 860, Chiron Diagnostic). All surgical procedures were 
performed under an operating stereomicroscope. 
 
III.10. Statistical analysis 
The data were evaluated as means ± SEM. Statistically significant 
differences among means were determined by ANOVA followed by Student-
Newman-Keuls test. The threshold for statistical significance data was set at 
p<0.05. 
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IV. RESULTS 
IV.1. Sp1 and Sp3 are bound in vivo to a specific region of ncx1-Br 
promoter sequence 
Since Sp1 and Sp3 both recognize GC-rich sequences known as GC boxes 
(Isomura et al., 2005), we searched for Sp1 sequences at the level of ncx1-
Br sequence (GenBank accession no. U95138), and subjected ncx1-Br 
sequence to computational prediction of transcriptional factors using the 
database TF SEARCH version 1.3 (Cassimere et al., 2009). As shown in Fig 
11a, five binding sites named Sp1 A-E located at -439/-431, -179/-170, -129/-
92, -111/-104 and -67/-58, from the transcriptional start site (TSS) on the 
ncx1-Br sequence have been identified. All these sequences have the TF 
search threshold score above 85.0. Experiments of ChIP assay were 
performed on extracts from cortical neurons that basally express Sp1, Sp3 
(Ryu et al., 2003a) and Sp4 (Ishimaru et al., 2007) to prove a direct 
association of Sp transcription factors with the ncx1-Br in the nuclear 
environment. To this aim ncx1-Br was divided in two different fragments 
named ncx1-Br (A) (-702/-387) ncx1-Br(B) (-366/+58), and experiments were 
performed using specific primers recognizing these two parts of ncx1-Br. As 
shown in Fig 11b, when chromatin was precipitated using antibodies for Sp1, 
Sp3 and Sp4, we were able to amplify only ncx1-Br (B), but not ncx1-Br (A) 
with Sp1 and Sp3 antibodies, compared to the IgG. Importantly, no signal 
was detected with the Sp4 antibody in the ncx1-Br (A) and (B) fragments (Fig 
11b). This result suggests that Sp4 does not bind ncx1-Br and that ncx1-Br 
(B), but not ncx1-Br (A) sequence is important for Sp1 and Sp3 binding in 
cortical neurons. 
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Figure 11. Transcription factors Sp1 and Sp3, but not Sp4, bind ncx1 brain promoter sequence 
from -380 to +58. (a) Map of the rat ncx1 gene indicating location of Sp1 sequences contained in distal 
(ncx1-Br A) and proximal (ncx1-Br B) regions of ncx1 brain promoter and of PCR primers used to 
detect the presence of specific DNA sequences in ChIP complexes. Triangles represent 5 Sp1 
identified motives in ncx1-Br, named Sp1 A-E. (b) ChIP analysis of ncx1-Br A and ncx1-Br B regions 
carried out with anti-Sp1, anti-Sp3 and anti-Sp4. Anti-IgG was used as negative control. The binding 
activity of Sp1, Sp3 and Sp4 is graphically represented as the percentage of total input of chromatin 
DNA. *P<0.05 vs IgG. Each column represents the mean ± s.e.m (n=3).  
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IV.2. Sp1 and Sp3 have an opposite effect on ncx1 luciferase activity, 
mRNA and protein expression  
To evaluate the effect of Sp transcription factors on ncx1 luciferase activity, 
mRNA and protein expression, neurons were silenced by specific siRNAs 
named siSp1, siSp3 and siSp4, that were able to decrease Sp1, Sp3 and 
Sp4 protein expression by 68%, 63% and 70%, respectively. In particular, for 
luciferase experiments we used a pGL3 construct contained the 5’-flanking 
region upstream of brain ncx1 transcriptional start site (+1), named short 
ncx1 promoter (pGL3-ncx1), already used in a previously paper (Valsecchi et 
al., 2011), including the native Sp1 consensus sequences from B to E, 
present in the ncx1-Br (B) fragment. As shown in Fig 12 a-c, at 24 hours 
luciferase assay, Real Time PCR (qRT–PCR) and at 48 hours western blot 
analysis revealed that in neurons ncx1 luciferase activity, transcript and 
protein decreased of 45%, 48% and 37% respectively with siSp1 and 
increased by 68%, 65% and 53% respectively with siSp3, whereas they did 
not modify by transfection of siSp4 or by co-transfection of double silencing 
for Sp1\Sp3, when compared to cells transfected with siCTL. To further 
confirm the role of Sp transcription factors in modulating NCX1 expression, 
neurons were transfected with constructs overexpressing Sp1, Sp3 and Sp4. 
that were able to increase Sp1, Sp3 and Sp4 protein expression by 69%, 
74% and 64%, respectively. As shown in Fig 12 d-f, in neurons 
overexpressing Sp1, luciferase activity and mRNA levels at 24 hours and 
protein levels at 48 hours of ncx1 were increased by 64%, 77% and 61% 
respectively, whereas cells overexpressing Sp3, luciferase activity and 
mRNA (24 hours) and protein levels (48 hours) were decreased by 76%, 
58% and 42%, respectively. As expected Sp4 overexpression and co-
transfection of Sp1 and Sp3 constructs did not cause any change of NCX1 
expression. To identify the critical Sp1 sequences within ncx1 promoter, the 
Sp1 binding sites B-E were mutated in the pGL3-ncx1 construct by site-direct 
mutagenesis in order to generate four different luciferase reporter constructs 
named Sp1 B mut, Sp1 C mut, Sp1 D mut and Sp1 E mut (Fig.13 a) and co-
transfected with an expression plasmid of Sp1 or of Sp3 in cortical neurons 
(Fig.13 b,c). When Sp1 was overexpressed, the luciferase activity of Sp1 C 
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mut, Sp1 D mut, Sp1 E mut was significantly inhibited by almost 30% (Fig.13 
b), whereas it was significantly increased by almost 35% when Sp3 was 
overexpressed (Fig.13 c), as compared with activity of pGL3-ncx1 in neurons 
overexpressing Sp1 or Sp3, respectively. For both the experimental 
conditions, mutation of Sp1 sequence B has no effect on ncx1 transcriptional 
activity (Fig.13 b,c). Interestingly, in neurons overexpressing Sp1 or Sp3, 
mutation of all three Sp1 sites C, D, E was able to further reduce by 65% or 
increase by 85% ncx1 promoter luciferase activity, compared to pGL3-ncx1 
alone, respectively (Fig.13 b,c). Altogether, these results demonstrate that 
Sp1 and Sp3 by three specific sequences interact with ncx1-Br promoter, 
determining an increase or a reduction of its expression, respectively. 
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Figure 12. Sp1 is a transcriptional activator whereas Sp3 is a transcriptional repressor of ncx1 
in cortical neurons. (a-c) luciferase assay of ncx1-Br, qRT–PCR and representative WB with 
quantification of NCX1 in control conditions (CTL) and after treatment with siCTL, siSp1, siSp3, siSp4, 
and in combination of siSp1 and siSp3 (n=4). Each column represents the mean ± s.e.m. (*P<0.05 vs 
pGL3 ncx1, siCTL). (d, f) luciferase assay of ncx1-Br, qRT–PCR and representative WB with 
quantification of NCX1 in control conditions (CTL) and after after transfection with pN3 or 
overexpression of Sp1, Sp3, Sp4, and after Sp1 and Sp3 together (n=3). Each column represents the 
mean ± s.e.m. (*P<0.05 vs pGL3 ncx1, pN3).  
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Figure 13. Effect of Sp1 and Sp3 on the transcriptional activity of the ncx1-Br after site-directed 
mutagenesis of the putative Sp1-binding sites. (a) The core consensus sequences of five putative 
Sp1 A–E sites are boxed and the locations relative to the reported transcription start site are separately 
numbered. Mutated nucleotides of the particular sequences are underlined and replaced nucleotides 
shown in italic below the wild-type sequences. The bent arrows indicate the reported transcription start 
site. (b, c) Cortical neurons transiently overexpressing Sp1 or Sp3 were co-transfected with pGL3-ncx1 
or pGL3-ncx1/Sp1Bmut, pGL3-ncx1/Sp1Cmut, pGL3-ncx1/Sp1Dmut, pGL3-ncx1/Sp1Emut and  pGL3-
ncx1/Sp1CDEmut constructs. 24 hours post-transfection, neurons were lysed in 1x passive lysis buffer. 
Lysates were analyzed for luciferase activity. The luciferase activity was expressed as firefly-to-renilla 
ratio. Each column represents the mean ± s.e.m. of n=4 independent experiments (*P<0.05 vs pGL3-
ncx1, **P<0.05 vs all). 
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IV.3. REST\Sp3 and HIF-1\Sp1 complexes co-localize on ncx1 brain 
promoter after tMCAO and PC+tMCAO, respectively 
The identified Sp1 sequences on the ncx1 Br are near the binding sites of 
previously characterized ncx1 transcriptional repressor REST, responsible for 
NCX1 decrease in cerebral ischemia (tMCAO) (Formisano et al., 2011) and 
of ncx1 transcriptional activator HIF-1, responsible of NCX1 increase after 
ischemic preconditioning followed by tMCAO (PC+tMCAO) (Valsecchi et al., 
2011). WB experiments were performed in the ipsilesional temporoparietal 
cortex of rats at 24 hrs after preconditioning (PC) alone, after tMCAO or 
PC+tMCAO, since REST, HIF-1 and NCX1 have already been investigated 
at this time point (Pignataro et al., 2011a; Valsecchi et al., 2011; Formisano 
et al., 2012). Interestingly, tMCAO induced a 44% reduction of NCX1, in 
parallel with an increase of HIF-1 (75%), REST (180%), and Sp3 (100%), but 
not of Sp1, when compared to the CTL (Fig.14 a-c, e). In addition, 
PC+tMCAO determined a remarkable increase of NCX1 by 140%, HIF-1 by 
450% and Sp1 by 180%, compared to the CTL, whereas REST and Sp3 
were reduced by 150% and by 154% respectively, compared to the cerebral 
ischemia values (Fig.14 a-e). Furthermore, PC+tMCAO-induced Sp3 
decrease was also significantly reduced compared to the CTL (Fig.14 e). PC 
alone did not significantly modify the expression of REST, HIF-1, Sp1, Sp3 
and NCX1, compared to the CTL (Fig.14 a-e). In all the experimental 
conditions Sp4 protein expression resulted not modified (Fig.14 f). Therefore, 
we evaluated the possible interaction of REST with Sp3 and of HIF-1 with 
Sp1, after tMCAO and PC+tMCAO, respectively. Interestingly, in rats 
subjected to cerebral ischemia, the binding to the ncx1-Br sequence was 
increased for RESTand Sp3 but not for HIF-1 and Sp1, compared to the CTL 
(Fig.15 a-d). On contrary, PC+tMCAO induced the binding of HIF-1 and Sp1 
on ncx1-Br sequence, but not of REST and Sp3, compared to the to the 
cerebral ischemia alone (Fig.15 a-d). We further conducted re-ChIP assay to 
test whether the transcriptional repressors REST and Sp3 or the 
transcriptional activators HIF-1 and Sp1 co-localized on the ncx1 Br 
sequence during tMCAO and PC+tMCAO respectively. Re-ChIP assay 
showed that Sp3 with REST (Fig.15e, lane 4) and HIF-1 with Sp1 (Fig.15f, 
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lane 4) were bound together on the ncx1 promoter after tMCAO, and after 
PC+tMCAO, respectively. These results suggest that Sp3 and REST form a 
functional complex on ncx1-Br sequence during tMCAO, whereas Sp1 and 
HIF-1 form another functional complex during PC+tMCAO. 
 
 
 
Figure 14. Effect of tMCAO and PC+tMCAO rat models on NCX1, HIF-1, REST, Sp1, Sp3 and Sp4 
in the ipsilateral temporoparietal cortex. (a-f) Representative WB with quantification of NCX1, HIF-
1, REST, Sp1, Sp3 and Sp4 protein expression in: (1) control group (CTL), (2) PC, (3) tMCAO and (4) 
PC+tMCAO.Each column represents the mean ± s.e.m. (n= 5 animals for each column) (*P<0.05 vs 
CTL, **P<0.05 vs all, 
#
P<0.05 vs tMCAO). 
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Figure 15. tMCAO and PC+tMCAO rat models promote REST/Sp3 and HIF-1/Sp1 colocalization 
on ncx1-Br in the ipsilateral temporoparietal cortex, respectively. (a-d) ChIP analysis of ncx1-Br in 
the ipsilateral temporoparietal cortex in: (1) CTL, (2) PC, (3) tMCAO and (4) PC+tMCAO. The binding 
activity of HIF-1, REST, Sp1 and Sp3 are graphically represented as the percentage of total input of 
chromatin DNA. Anti-IgG was used as negative control. Each column represents the mean ± s.e.m. (n= 
6 animals for each column) (*P<0.05 vs CTL,). (e-f)Re-ChIP analysis of ncx1-Br in the ipsilateral 
temporoparietal cortex in: (1) CTL, (2) PC, (3) tMCAO and (4) PC+tMCAO. Primary ChIP products for 
anti-Sp3 and anti-Sp1 (I Ab) were subjected to re-ChIP with anti-REST, anti-HIF-1, respectively, or with 
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anti-IgG (II Ab). The input DNA lane represents 5% of the precleared chromatin used in each ChIP 
reaction. The figure is representative of two independent experiments. 
IV.4. Epigenetic remodeling of ncx1-Br promoter by HDAC1 and HDAC2 
after tMCAO and by p300 after PC+tMCAO, respectively 
Since the transcription factors REST, HIF-1, Sp1, and Sp3 regulate their 
target genes by epigenetic modifications, such as acetylation (Won et al., 
2002; Formisano et al., 2007; Azahri et al., 2012; Noh et al., 2012; Pawlus 
and Hu, 2013). We evaluated by ChIP assay the modification of the 
acetylated histone protein H3 and the binding of HDAC1, HDAC2, histone 
acetyltransferase p300 and RNA polymerase II (RNA-Pol II) on ncx1-Br 
promoter sequence in the ipsilesional temporoparietal cortex of the following 
groups: (1) control group (CTL), (2) PC, (3) tMCAO, (4) PC+tMCAO.As 
shown in Fig.16a,b, tMCAO reduced the abundance of ncx1 promoter 
associated with acetylated H3 and RNA-Pol II in parallel with an increase of 
the binding of HDAC1 and HDAC2 (Fig.16 c,d), that are recruited by REST 
to promote gene silencing, compared to the CTL. During tMCAO, p300 
binding on ncx1 promoter was absent, as shown in Fig. 16 e. Interestingly, 
there was no HDAC1\2 binding on ncx1-Br when the animals were exposed 
to PC+tMCAO (Fig.16 c,d). In contrast, PC+tMCAO increased the 
abundance of ncx1-Br associated with acetylated H3, in parallel with an 
increase of RNA-Pol II and p300 binding, that is known to mediate the 
activation of HIF-1 target genes, compared to the CTL (Fig.16 a, b, e). To 
better understand the role of REST, Sp3 and HDAC1\2 on the tMCAO-
induced NCX1 reduction, experiments of ChIP, qRT-PCR and WB were 
performed to evaluate the acetylation status of ncx1-Br, ncx1 gene and 
protein expression, by icv injection of siSp3, siREST, alone or in combination, 
and by double silencing for HDAC1\2. As shown in Fig.17 a-c, tMCAO-
induced ncx1-Br deacetylation and ncx1 gene and protein decrease were 
reverted by the silencing of the all above mentioned proteins, compared to 
the CTL. Next, we studied the role of HIF-1, Sp1 and p300 in the 
PC+tMCAO-induced NCX1 increase by ChIP, qRT-PCR and WB analysis, 
after icv injection of siSp1, siHIF-1, alone or in combination, and by silencing 
for p300. As shown in Fig.17 d-f, PC+tMCAO-induced hyperacetylation of 
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histone H3 on ncx1-Br and ncx1 gene and protein increase were reverted by 
knocking down with specific siRNA of Sp1, HIF-1, alone or in combination, 
and p300, compared to the CTL. 
 
Figure 16. Effect of tMCAO and PC+tMCAO rat models on H3 acetylation, RNA-Pol II, HDAC1, 
HDAC2 and p300 binding to ncx1-Br. (a-e) ChIP analysis of ncx1-Br in the ipsilateral temporoparietal 
cortex in: (1) CTL, (2) PC, (3) tMCAO and (4) PC+tMCAO. The binding activity of H3 acetyl, RNA-Pol 
II, HDAC1, HDAC2 and p300 are graphically represented as the percentage of total input of chromatin 
DNA. IgG was used as negative control. Each column represents the mean ± s.e.m. (n= 6 animals for 
each column) (*P<0.05 vs CTL, **P<0.05 vs all). 
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Figure 17. NCX1 is epigenetically modulated by Sp3/REST/HDAC1/2 complex in tMCAO and by 
Sp1/HIF-1/p300 in PC+tMCAO. (a) ChIP analysis with anti-H3 acetyl of ncx1-Br in CTL and in tMCAO 
after icv injection of siSp3, siREST, siREST+siSp3, siHDAC1+siHDAC2. IgG was used as negative 
control. Each column represents the mean ± s.e.m. (n= 5 animals for each column) (*P<0.05 vs CTL, 
**P<0.05 vs all). (b, c) qRT–PCR and representative WB with quantification of NCX1 in CTL and in 
tMCAO after icv injection of siCTL, siSp3, siREST, siREST+siSp3, siHDAC1+siHDAC2. Each column 
represents the mean ± s.e.m. of n=6 independent experiments (*P<0.05 vs CTL, **P<0.05 vs all). (d) 
ChIP analysis with anti-H3 acetyl of ncx1-Br in CTL and in PC+tMCAO after icv injection of siCTL, 
siSp1, siHIF-1, siSp1+siHIF-1 and sip300. IgG was used as negative control. Each column represents 
the mean ± s.e.m. (n= 6 animals for each column) (*P<0.05 vs CTL). (e, f) qRT–PCR and 
representative WB with quantification of NCX1 in CTL and PC+tMCAO after icv injection of siCTL, 
siSp1, siHIF-1, siSp1+siHIF-1 and sip300. Each column represents the mean ± s.e.m. (n= 6 animals 
for each column) (*P<0.05 vs CTL). 
 
IV.5. A class I HDAC inhibitor MS-275, by increasing NCX1 expression 
during OGD/Rx, reduces neuronal cell death  
Since HDAC1 and HDAC2 belong to class I histone deacetylases (Chuang et 
al., 2009a), we evaluated the effect of class I HDAC inhibitor MS-275, used 
at the concentration of 1µM in cortical neurons exposed to OGD/Rx 
(Lanzillotta et al., 2012). Firstly, the specificity of MS-275 to inhibit class I 
HDAC was validated by measuring the levels of acetylated forms of histone 
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H3 (indicating activity of class I) (Simonini et al., 2006; Galmozzi et al., 2013). 
Results showed that MS-275 increased the acetylation of histone H3 (Fig.18 
a). As shown in Fig.18 b, MS-275 exerted a remarkable neuroprotective 
effect, by preventing  cell death observed in OGD/Rx and siNCX1 (1μg) 
counteracted this neuroprotective effect. To identify the role of NCX1 in MS-
275-induced neuroprotection, western blot analysis were performed for NCX1 
in the same experimental conditions. Furthermore, exposure of cortical 
neurons to OGD/Rx+MS-275 induced an increase in NCX1 protein 
expression compared to the OGD/Rx+vehicle (Fig.18 c). As expected, MS-
275-induced NCX1 increase was counteracted by siNCX1 (Fig.18 c).  
 
IV.6. Hystone acetyl transferase p300 inhibitor C646 blocks PC-induced 
neuroprotection, by counteracting NCX1 increase 
We investigated the hypothesis that PC exerts a neuroprotective effect in 
cortical neurons exposed to OGD/Rx via the increase of p300 and NCX1 
expression. The specificity of C646 to inhibit Hystone acetyl transferase p300 
was validated by measuring the levels of acetylated forms of histone H3 
(Federman et al., 2013). Results showed that C646 decreased the 
acetylation of histone H3 (Fig.18 d). As shown in Fig.18 e, in neurons 
exposed to PC+OGD/Rx, the p300 inhibitor C646 at 20 μM (Min et al., 2010) 
was able to reduce cell survival compared to PC+OGD/Rx+vehicle. 
Interestingly, NCX1 overexpression was able to counteract C646-induced cell 
death, compared to PC+OGD/Rx+vector (Fig. 18 e). To confirm the role of 
NCX1 in PC-induced neuroprotection, experiments of WB were performed to 
analyze NCX1 expression. As shown in Fig. 18 e, C646 prevented the 
increase of NCX1, in cortical neurons exposed to PC+OGD/Rx and this effect 
was counteracted by NCX1 overexpression.  
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Figure 18. Effect of class I HDAC inhibitor MS-275 and of HAT p300 inhibitor C646 on cell 
survival and NCX1 protein expression in cortical neurons exposed to OGD/Rx or to 
PC+OGD/Rx, respectively. (a) representative WB with quantification of H3 acetyl in neurons 
subjected to OGD/Rx alone or with MS-275. Each column represents the mean ± s.e.m. of n=3 
independent experiments (*P<0.05 vs OGD/Rx). (b, c) LDH assay and NCX1 protein expression with 
quantification in (1) control condition (CTL), (2) OGD/Rx (3) OGD/Rx+vehicle, (4) OGD/Rx+siCTL, (5) 
OGD/Rx+MS-275 (1µM), (6) OGD/Rx+MS-275+siNCX1. Each column represents the mean ± s.e.m. of 
n=4 independent experiments for LDH assay, and n=3 for WB. (*P<0.05 vs CTL, **P<0.05 vs all, 
#
P<0.05 vs OGD/Rx+MS-275). (d) representative WB with quantification of H3 acetyl in neurons 
subjected to PC+OGD/Rx alone or with C646. Each column represents the mean ± s.e.m. of n=3 
independent experiments (*P<0.05 vs OGD/Rx). (e, f) LDH assay and NCX1 protein expression with 
quantification in (1) CTL, (2) PC, (3) OGD/Rx, (4) PC+OGD/Rx, (5) PC+OGD/Rx+vehicle, (6) 
PC+OGD/Rx+Empty vector, (7) PC+OGD/Rx+C646, (8) PC+OGD/Rx+C646+NCX1. Each column 
represents the mean ± s.e.m. of n=3 independent experiments for LDH assay, and n=3 for WB. 
(*P<0.05 vs CTL, **P<0.05 vs all, 
#
P<0.05 vs PC+OGD/Rx alone or with vehicle and empty vector, 
^
P<0.05 vs PC+OGD/Rx+C646). 
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V. DISCUSSION 
This study has evidenced for the first time that NCX1 expression is 
epigenetically down-regulated in brain ischemia by Sp3\REST complex and 
up-regulated in brain ischemic preconditioning by Sp1\HIF-1 complex. 
Particularly, our results suggest that Sp3 with REST and Sp1 with HIF-1 form 
a functional complex on ncx1-Br sequence in brain ischemia and in brain 
ischemic preconditioning, respectively. In fact, we showed that REST\Sp3-
induced NCX1 down-regulation after tMCAO and HIF-1\Sp1-induced NCX1 
up-regulation after PC+tMCAO are associated to their expression, since icv 
injection of siREST and siSp3, alone or in combination, in brain ischemia and 
of siHIF-1 and siSp1, alone or in combination, in brain ischemic 
preconditioning completely reverts NCX1 mRNA and protein decrease or 
increase, respectively. On the other hand, a cross-talk between Sp1, Sp3 
and REST to regulate their target genes has been already proposed. In 
particular, Sp1 acts as an activator for the expression of REST target genes 
(Plaisance et al., 2005), while Sp3 by binding GC box interacts with REST to 
repress the mu opioid receptor expression (Kim et al., 2006). Furthermore, 
hypoxic condition induced expression of Regulated in development and DNA 
damage response 1 (Redd1), that is mediated by coactivation of Sp1 and 
HIF-1 (Jin et al., 2007). Interestingly, in the present paper we have identified 
five Sp1 motifs in the rat ncx1-Br, located at -439, -179, -129, -111, -67 from 
the TSS, named Sp1 A-E, as the possible molecular determinants involved in 
Sp1 isoforms-induced ncx1 regulation. Furthermore, we found that among 
the family of transcription factors Sp, only Sp1 and Sp3, but not Sp4, bind to 
ncx1-Br in a very selective manner, as revealed by ChIP analyses. Our 
results are in line with data showing that Sp1 and Sp3 regulate target genes 
transcription via binding to identical cognate DNA elements with similar 
affinities (Hagen et al., 1992). Indeed, transfection in cortical neurons of 
specific siRNAs for Sp1 and Sp3 produced, respectively, a decrease or an 
increase in the ncx1 promoter activity, mRNA and protein expression and 
conversely, combined transfection of siRNAs of Sp1\Sp3 did not induce any 
change in ncx1 promoter activity, mRNA and protein expression. These 
results demonstrate that Sp1 is an activator while Sp3 is a repressor of ncx1 
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transcription, a mechanism also reported for other Sp1 isoforms gene target 
(Stains et al., 2003). Notably, in the present paper we identified three Sp1 
binding sites (C-E) on ncx1-Br that show the highest promoter activity and 
found that mutation analysis at the level of Sp1C-E sites in neurons 
overexpressing Sp1 and Sp3 significantly reduces or increases the activity of 
ncx1 brain promoter, respectively, whereas Sp1-B mutation has no effect. 
Collectively, these results show that three of the five Sp1 elements present 
on ncx1-Br sequence modulate the promoter activity of the ncx1 gene. It is 
known that global transcriptional repression upon ischemia is similarly 
reflected on the decrease of histones acetylation, and that HDAC inhibition 
reduces ischemia-induced alterations in HDAC expression, by determining 
neuroprotection (Abel and Zukin, 2008; Noh et al., 2012). Data emerging 
from our study seem to suggest that both REST during ischemia and HIF-1 
during preconditioning interfere with NCX1 gene expression through the 
participation of HDAC1, HDAC2 and p300. In particular, in brain ischemia by 
ChIP analysis we found that REST and Sp3 together with the corepressors 
HDAC1 and HDAC2 are recruited to the ncx1-Br decreasing H3 acetylation 
and RNA-Pol II binding and determining a reduction of ncx1 mRNA and 
protein expression. Regarding the relationship between HIF-1 and p300 
during preconditioning, our results showed that PC+tMCAO increases the 
abundance of ncx1-Br associated with acetylated H3, in parallel with an 
increase of RNA-Pol II, HIF-1 and p300 binding, determining an increase of 
NCX1 mRNA and protein expression. All these results together suggest that 
the complex REST\Sp3\HDAC1,2 decreases NCX1 expression during brain 
ischemia, whereas the complex HIF-1\Sp1\p300 increases the expression of 
this gene during preconditioning. Interestingly, this regulation regards 
exclusively NCX1 isoform, but not NCX3 isoform, that is also involved in the 
mechanisms of brain ischemia and of ischemic brain preconditioning 
(Pignataro et al., 2011a). Indeed, changes in NCX3 mRNA and protein 
expression were not caused by REST\Sp3\HDAC1,2 complex in brain 
ischemia and by HIF-1\Sp1\p300 complex in ischemic brain preconditioning. 
Since it has been widely demonstrated by our group that NCX1 expression is 
involved in the pathophysiology of brain ischemia and in the protection 
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exerted by preconditioning, we investigated the role of HDAC1,2 and p300 on 
NCX1-induced neuroprotection in neurons subjected to OGD\Rx, a model 
resembling brain ischemia, and to PC+OGD\Rx. The results of these 
experiments showed that HDAC1-2 inhibitor MS-275-induced 
neuroprotection is completely abolished in OGD\Rx by silencing of NCX1, 
thus further supporting the tight relationship existing between HDAC1-2 and 
NCX1 in the pathophysiological processes leading to stroke. These results 
are in accordance with Noh et al. (2012) showing that HDAC1 and 2 are 
recruited to the AMPA receptor subunit GluA2 promoter sequence, and that 
injection of pan-HDAC inhibitor thrichostatin A, an inhibitor of key 
components of the REST–corepressor complex, HDAC1 and HDAC2, 
administered to animals after an ischemic episode, ameliorates neuronal 
injury. In addition, p300 inhibitor C646-induced cell death is completely 
reverted in PC+OGD\Rx by NCX1 overexpression, thus suggesting a close 
relationship between the histone acetyltransferase p300 and NCX1 in the 
ischemic preconditioning. In light of all these findings, the development of 
drugs that epigenetically regulate NCX1, through the prevention of its down-
regulation in stroke, or that increase its expression, as occured in 
PC+tMCAO, might be a new pharmacological strategy to ameliorate neuronal 
damage during brain ischemia.  
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